ZA200603031B - Fused heterocyclic componds as serotonin receptor modulators - Google Patents
Fused heterocyclic componds as serotonin receptor modulators Download PDFInfo
- Publication number
- ZA200603031B ZA200603031B ZA200603031A ZA200603031A ZA200603031B ZA 200603031 B ZA200603031 B ZA 200603031B ZA 200603031 A ZA200603031 A ZA 200603031A ZA 200603031 A ZA200603031 A ZA 200603031A ZA 200603031 B ZA200603031 B ZA 200603031B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- triaza
- hexahydro
- azulene
- substituted
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 51
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title claims description 17
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title claims description 17
- -1 -CF Chemical group 0.000 claims description 303
- 229910052799 carbon Inorganic materials 0.000 claims description 282
- 125000000217 alkyl group Chemical group 0.000 claims description 228
- 125000004432 carbon atom Chemical group C* 0.000 claims description 130
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 122
- 229910052739 hydrogen Inorganic materials 0.000 claims description 119
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 110
- 150000001721 carbon Chemical group 0.000 claims description 100
- 150000001875 compounds Chemical class 0.000 claims description 81
- 125000001424 substituent group Chemical group 0.000 claims description 79
- 125000004076 pyridyl group Chemical group 0.000 claims description 70
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims description 61
- 125000005843 halogen group Chemical group 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 50
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 229920000728 polyester Polymers 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 40
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 40
- 150000002430 hydrocarbons Chemical group 0.000 claims description 40
- 125000006413 ring segment Chemical group 0.000 claims description 40
- 125000002950 monocyclic group Chemical group 0.000 claims description 39
- 150000001408 amides Chemical class 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 125000001544 thienyl group Chemical group 0.000 claims description 33
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000005842 heteroatom Chemical group 0.000 claims description 31
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 28
- RMUDBHOUKWNOLH-UHFFFAOYSA-N pyrazolo[3,4-d]azepine Chemical compound C1=CN=CC=C2C=NN=C21 RMUDBHOUKWNOLH-UHFFFAOYSA-N 0.000 claims description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 125000001624 naphthyl group Chemical group 0.000 claims description 23
- 125000002541 furyl group Chemical group 0.000 claims description 22
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000002971 oxazolyl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 13
- XVYPKEBYTBRBEC-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrazolo[3,4-d]azepine Chemical compound C1=NCCC2CNNC2=C1 XVYPKEBYTBRBEC-UHFFFAOYSA-N 0.000 claims description 12
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 12
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 150000004677 hydrates Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 3
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 3
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 229940076279 serotonin Drugs 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims description 2
- DZRPZHFRFRYSKM-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(2-ethylbutyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=2CCNCCC=2N(CC(CC)CC)N=C1C1=CC=C(Cl)C=C1 DZRPZHFRFRYSKM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004820 3-methylbutylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical group C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 claims description 2
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 229940070765 laurate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000003068 molecular probe Substances 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000005487 naphthalate group Chemical group 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940039748 oxalate Drugs 0.000 claims description 2
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 229940075993 receptor modulator Drugs 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 4
- JAWBBUARDVCNSH-UHFFFAOYSA-N 2-butan-2-yl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCC(C)N1N=C2CCNCCC2=C1C1=CC=C(C)C=C1 JAWBBUARDVCNSH-UHFFFAOYSA-N 0.000 claims 3
- YYCVTBSEGMPXJR-UHFFFAOYSA-N 2-cyclopropyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C1=C(CCNCC2)C2=NN1C1CC1 YYCVTBSEGMPXJR-UHFFFAOYSA-N 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- ARFWKBWXBMDBHD-UHFFFAOYSA-N 1-benzyl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound N1=C(C=2SC=CC=2)C=2CCNCCC=2N1CC1=CC=CC=C1 ARFWKBWXBMDBHD-UHFFFAOYSA-N 0.000 claims 2
- SAYQOIDIBFKAAI-UHFFFAOYSA-N 2-benzyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound N1=C2CCNCCC2=C(C=2C=CC=CC=2)N1CC1=CC=CC=C1 SAYQOIDIBFKAAI-UHFFFAOYSA-N 0.000 claims 2
- KRSWZAPAEZRNQN-UHFFFAOYSA-N 2-cyclobutyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCC1 KRSWZAPAEZRNQN-UHFFFAOYSA-N 0.000 claims 2
- QEUUGUOVKZCUGI-UHFFFAOYSA-N 2-cyclobutyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C1=C(CCNCC2)C2=NN1C1CCC1 QEUUGUOVKZCUGI-UHFFFAOYSA-N 0.000 claims 2
- AUBZKCKTPAZIBA-UHFFFAOYSA-N 2-cyclohexyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCCC1N1C(C=2C=CC=CC=2)=C2CCNCCC2=N1 AUBZKCKTPAZIBA-UHFFFAOYSA-N 0.000 claims 2
- IWPAPSIKRTYFSR-UHFFFAOYSA-N 2-cyclopentyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 IWPAPSIKRTYFSR-UHFFFAOYSA-N 0.000 claims 2
- GKOQTZCERQKJIL-UHFFFAOYSA-N 2-cyclopentyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 GKOQTZCERQKJIL-UHFFFAOYSA-N 0.000 claims 2
- YWDRKJSRKOKSPZ-UHFFFAOYSA-N 2-cyclopentyl-3-(furan-3-yl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCC1N1C(C2=COC=C2)=C2CCNCCC2=N1 YWDRKJSRKOKSPZ-UHFFFAOYSA-N 0.000 claims 2
- RDIWXHPRIFAFII-UHFFFAOYSA-N 2-cyclopentyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCC1N1C(C=2C=CC=CC=2)=C2CCNCCC2=N1 RDIWXHPRIFAFII-UHFFFAOYSA-N 0.000 claims 2
- XWPJSQOMCNOCPX-UHFFFAOYSA-N 2-cyclopentyl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCC1N1C(C=2SC=CC=2)=C2CCNCCC2=N1 XWPJSQOMCNOCPX-UHFFFAOYSA-N 0.000 claims 2
- YMAWHDMSUKUZLY-UHFFFAOYSA-N 2-cyclopentyl-3-thiophen-3-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CCCC1N1C(C2=CSC=C2)=C2CCNCCC2=N1 YMAWHDMSUKUZLY-UHFFFAOYSA-N 0.000 claims 2
- PBVYEZOTEXRPPS-UHFFFAOYSA-N 2-cyclopentyl-7-methyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C=1C=C(C)C=CC=1C1=C2CCNC(C)CC2=NN1C1CCCC1 PBVYEZOTEXRPPS-UHFFFAOYSA-N 0.000 claims 2
- BJYUYYIMVOZLEA-UHFFFAOYSA-N 2-ethyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=C(C)C=C1 BJYUYYIMVOZLEA-UHFFFAOYSA-N 0.000 claims 2
- QPQPXZQRZGVLOY-UHFFFAOYSA-N 2-tert-butyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)(C)N1N=C2CCNCCC2=C1C1=CC=C(F)C=C1 QPQPXZQRZGVLOY-UHFFFAOYSA-N 0.000 claims 2
- BMBDVPYNNCFDNT-UHFFFAOYSA-N 2-tert-butyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)(C)N1N=C2CCNCCC2=C1C1=CC=CC=C1 BMBDVPYNNCFDNT-UHFFFAOYSA-N 0.000 claims 2
- MBYKZXBKGIFYNT-UHFFFAOYSA-N 3-(3-chloro-4-fluorophenyl)-2-cyclopentyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(Cl)C(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 MBYKZXBKGIFYNT-UHFFFAOYSA-N 0.000 claims 2
- WHGQWMKZHVRSLF-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-fluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC=CC(CN2C=3CCNCCC=3C(=N2)C=2C=CC(Cl)=CC=2)=C1 WHGQWMKZHVRSLF-UHFFFAOYSA-N 0.000 claims 2
- UUWHVKPIADRQCX-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC1=CC=CC(CN2C=3CCNCCC=3C(=N2)C=2C=CC(Cl)=CC=2)=C1 UUWHVKPIADRQCX-UHFFFAOYSA-N 0.000 claims 2
- VDQJMTDHVWYIEQ-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 VDQJMTDHVWYIEQ-UHFFFAOYSA-N 0.000 claims 2
- UYAQBYKCVBOSOK-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-cyclobutyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1C1CCC1 UYAQBYKCVBOSOK-UHFFFAOYSA-N 0.000 claims 2
- DGXOEQXJGRVGTM-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-cyclopentyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 DGXOEQXJGRVGTM-UHFFFAOYSA-N 0.000 claims 2
- HCYYQTSWPWEMHS-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-ethyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 HCYYQTSWPWEMHS-UHFFFAOYSA-N 0.000 claims 2
- HXAOXQVRMJLJNW-UHFFFAOYSA-N 3-(4-ethylphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(CC)=CC=C1C1=C(CCNCC2)C2=NN1C(C)C HXAOXQVRMJLJNW-UHFFFAOYSA-N 0.000 claims 2
- RBYJHELKTYHZNG-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C(F)C=C1 RBYJHELKTYHZNG-UHFFFAOYSA-N 0.000 claims 2
- VMLAIZMHNUQKOX-UHFFFAOYSA-N 3-(4-fluorophenyl)-8-methyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2C(C)CNCCC2=C1C1=CC=C(F)C=C1 VMLAIZMHNUQKOX-UHFFFAOYSA-N 0.000 claims 2
- DYBWPBGEFFIVCW-UHFFFAOYSA-N 4-(2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C(C#N)C=C1 DYBWPBGEFFIVCW-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 230000030135 gastric motility Effects 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WPHGSKGZRAQSGP-UHFFFAOYSA-N norcarane Chemical compound C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- PUMCNFNJQPLHTL-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrazolo[4,3-c]azepine Chemical compound C1=CNCC2CNNC2=C1 PUMCNFNJQPLHTL-UHFFFAOYSA-N 0.000 claims 1
- MASWQYAPUWTJNT-UHFFFAOYSA-N 1-[(2-bromophenyl)methyl]-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1Br MASWQYAPUWTJNT-UHFFFAOYSA-N 0.000 claims 1
- JTLKOCQOBQJLFP-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=C(Br)C=C1 JTLKOCQOBQJLFP-UHFFFAOYSA-N 0.000 claims 1
- PZGRYZYEQXJRMV-UHFFFAOYSA-N 1-[[3,4-bis(phenylmethoxy)phenyl]methyl]-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC(C=C1OCC=2C=CC=CC=2)=CC=C1OCC1=CC=CC=C1 PZGRYZYEQXJRMV-UHFFFAOYSA-N 0.000 claims 1
- OVFGYHAAKOALDT-UHFFFAOYSA-N 1-benzyl-3-(2,3-difluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC=CC(C=2C=3CCNCCC=3N(CC=3C=CC=CC=3)N=2)=C1F OVFGYHAAKOALDT-UHFFFAOYSA-N 0.000 claims 1
- OWFNZOFQLPEVIQ-UHFFFAOYSA-N 1-benzyl-3-(2-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 OWFNZOFQLPEVIQ-UHFFFAOYSA-N 0.000 claims 1
- DBCHBJAYLUPYGO-UHFFFAOYSA-N 1-benzyl-3-(3,4-dichlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 DBCHBJAYLUPYGO-UHFFFAOYSA-N 0.000 claims 1
- NBPFUGHPIWZZOO-UHFFFAOYSA-N 1-benzyl-3-(3-chloro-4-fluorophenyl)-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=C(Cl)C(F)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1 NBPFUGHPIWZZOO-UHFFFAOYSA-N 0.000 claims 1
- DIQZMBPDLFAJLK-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 DIQZMBPDLFAJLK-UHFFFAOYSA-N 0.000 claims 1
- HSUSOKSRYOCAIB-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)-5-ethyl-6,7-dihydro-4h-pyrrolo[3,2-c]pyridine Chemical compound C1N(CC)CCC2=C1C(C=1C=CC(Cl)=CC=1)=CN2CC1=CC=CC=C1 HSUSOKSRYOCAIB-UHFFFAOYSA-N 0.000 claims 1
- JVPZQCJUBCGWNI-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)-6-[(3,4-dimethoxyphenyl)methyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=C(OC)C(OC)=CC=C1CN1CCC(N(CC=2C=CC=CC=2)N=C2C=3C=CC(Cl)=CC=3)=C2CC1 JVPZQCJUBCGWNI-UHFFFAOYSA-N 0.000 claims 1
- AZRCZQSGEJOJKS-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)-6-ethyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=2CCN(CC)CCC=2C(C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 AZRCZQSGEJOJKS-UHFFFAOYSA-N 0.000 claims 1
- FPZBBELNXZMZNO-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)-6-methyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1=2CCN(C)CCC=2C(C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 FPZBBELNXZMZNO-UHFFFAOYSA-N 0.000 claims 1
- JMRVHBJXROYVQP-UHFFFAOYSA-N 1-benzyl-3-(4-methylphenyl)-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(C)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1 JMRVHBJXROYVQP-UHFFFAOYSA-N 0.000 claims 1
- WDOMRVMNRGQYBW-UHFFFAOYSA-N 1-benzyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 WDOMRVMNRGQYBW-UHFFFAOYSA-N 0.000 claims 1
- JZHOADSBUGKCTH-UHFFFAOYSA-N 1-benzyl-3-[4-(trifluoromethoxy)phenyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1 JZHOADSBUGKCTH-UHFFFAOYSA-N 0.000 claims 1
- WTWATPMKSBRAEN-UHFFFAOYSA-N 1-benzyl-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 WTWATPMKSBRAEN-UHFFFAOYSA-N 0.000 claims 1
- KITFKDHTXXEJFK-UHFFFAOYSA-N 1-benzyl-3-[4-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1 KITFKDHTXXEJFK-UHFFFAOYSA-N 0.000 claims 1
- QIJGWWIAMMEZTK-UHFFFAOYSA-N 1-benzyl-3-phenyl-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=C(C=2C=CC=CC=2)C=2CNCCC=2N1CC1=CC=CC=C1 QIJGWWIAMMEZTK-UHFFFAOYSA-N 0.000 claims 1
- ALARUGXUHKKHED-UHFFFAOYSA-N 1-benzyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound N1=C(C=2C=CC=CC=2)C=2CCNCCC=2N1CC1=CC=CC=C1 ALARUGXUHKKHED-UHFFFAOYSA-N 0.000 claims 1
- ZBVVROSLXTXVBW-UHFFFAOYSA-N 1-benzyl-3-phenyl-6-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CN(C(C)C)CCC(C(=N2)C=3C=CC=CC=3)=C1N2CC1=CC=CC=C1 ZBVVROSLXTXVBW-UHFFFAOYSA-N 0.000 claims 1
- CIXILMMDWGHSTA-UHFFFAOYSA-N 1-benzyl-3-phenyl-6-propyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CN(CCC)CCC(C(=N2)C=3C=CC=CC=3)=C1N2CC1=CC=CC=C1 CIXILMMDWGHSTA-UHFFFAOYSA-N 0.000 claims 1
- MURUSNHOZHOJGZ-UHFFFAOYSA-N 1-butyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=2CCNCCC=2N(CCCC)N=C1C1=CC=C(Cl)C=C1 MURUSNHOZHOJGZ-UHFFFAOYSA-N 0.000 claims 1
- KULCRQXLMJYMKI-UHFFFAOYSA-N 1-butyl-3-(4-chlorophenyl)-6-[(3,4-dimethoxyphenyl)methyl]-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CC=2N(CCCC)N=C(C=3C=CC(Cl)=CC=3)C=2CCN1CC1=CC=C(OC)C(OC)=C1 KULCRQXLMJYMKI-UHFFFAOYSA-N 0.000 claims 1
- RNDBKSSLRCCKNJ-UHFFFAOYSA-N 1-butyl-3-(4-methylphenyl)-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=2CNCCC=2N(CCCC)C=C1C1=CC=C(C)C=C1 RNDBKSSLRCCKNJ-UHFFFAOYSA-N 0.000 claims 1
- LRHYQYOSIPKHEJ-UHFFFAOYSA-N 2,3-diphenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine Chemical compound C=12CNCCC2=NN(C=2C=CC=CC=2)C=1C1=CC=CC=C1 LRHYQYOSIPKHEJ-UHFFFAOYSA-N 0.000 claims 1
- MXOUMFAGXNVEAJ-UHFFFAOYSA-N 2,3-diphenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C=12CCNCCC2=NN(C=2C=CC=CC=2)C=1C1=CC=CC=C1 MXOUMFAGXNVEAJ-UHFFFAOYSA-N 0.000 claims 1
- QNDFDBVEHJNKPY-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)-3-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC(F)(F)CN1N=C2CCNCCC2=C1C1=CC=C(C(F)(F)F)C=C1 QNDFDBVEHJNKPY-UHFFFAOYSA-N 0.000 claims 1
- QZPIAOOFCAMYNF-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound ClC1=CC=CC=C1N1C(C=2C=CC=CC=2)=C2CCNCCC2=N1 QZPIAOOFCAMYNF-UHFFFAOYSA-N 0.000 claims 1
- GQBRWCDRNVFJED-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound ClC1=CC=CC(N2C(=C3CCNCCC3=N2)C=2C=CC=CC=2)=C1 GQBRWCDRNVFJED-UHFFFAOYSA-N 0.000 claims 1
- FLUMMHHYHRBUOV-UHFFFAOYSA-N 2-[1-benzyl-3-(4-chlorophenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-6-yl]acetamide Chemical compound C1CN(CC(=O)N)CCC(C(=N2)C=3C=CC(Cl)=CC=3)=C1N2CC1=CC=CC=C1 FLUMMHHYHRBUOV-UHFFFAOYSA-N 0.000 claims 1
- NKYYOHBWTDFDPI-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]-n,n-dimethylethanamine Chemical compound C1=2CCNCCC=2N(CCN(C)C)N=C1C1=CC=C(Cl)C=C1 NKYYOHBWTDFDPI-UHFFFAOYSA-N 0.000 claims 1
- GZRAOBPFHIJZJO-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]-n-methylacetamide Chemical compound C1=2CCNCCC=2N(CC(=O)NC)N=C1C1=CC=C(Cl)C=C1 GZRAOBPFHIJZJO-UHFFFAOYSA-N 0.000 claims 1
- XMBNGGVVQVVMHI-UHFFFAOYSA-N 2-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CC1=CC=CC=C1 XMBNGGVVQVVMHI-UHFFFAOYSA-N 0.000 claims 1
- KLKVELNNYWYTMU-UHFFFAOYSA-N 2-benzyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1C1=C(CCNCC2)C2=NN1CC1=CC=CC=C1 KLKVELNNYWYTMU-UHFFFAOYSA-N 0.000 claims 1
- YKYOWOJCWZUVON-UHFFFAOYSA-N 2-butan-2-yl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCC(C)N1N=C2CCNCCC2=C1C1=CC=CC=C1 YKYOWOJCWZUVON-UHFFFAOYSA-N 0.000 claims 1
- QHIWRPRGWRPPRW-UHFFFAOYSA-N 2-butyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCCCN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 QHIWRPRGWRPPRW-UHFFFAOYSA-N 0.000 claims 1
- GPJWIZYNTCBZFV-UHFFFAOYSA-N 2-cyclobutyl-3-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCC1 GPJWIZYNTCBZFV-UHFFFAOYSA-N 0.000 claims 1
- YPQWXYQYMKXSQE-UHFFFAOYSA-N 2-cyclohexyl-3-(3,4-difluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 YPQWXYQYMKXSQE-UHFFFAOYSA-N 0.000 claims 1
- BLWAJWFMWZDRJP-UHFFFAOYSA-N 2-cyclohexyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 BLWAJWFMWZDRJP-UHFFFAOYSA-N 0.000 claims 1
- ZKUXBXHJBYCAKJ-UHFFFAOYSA-N 2-cyclohexyl-3-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(OC)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 ZKUXBXHJBYCAKJ-UHFFFAOYSA-N 0.000 claims 1
- XASVUVFCEKAAAV-UHFFFAOYSA-N 2-cyclohexyl-3-(4-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 XASVUVFCEKAAAV-UHFFFAOYSA-N 0.000 claims 1
- VXTCELKLMRKJJC-UHFFFAOYSA-N 2-cyclopentyl-3-(3,4-difluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 VXTCELKLMRKJJC-UHFFFAOYSA-N 0.000 claims 1
- GDKQBABXYRBLIR-UHFFFAOYSA-N 2-cyclopentyl-3-(4-fluorophenyl)-5,5,7,7-tetramethyl-6,8-dihydro-4h-pyrazolo[3,4-d]azepine Chemical compound C=1C=C(F)C=CC=1C1=C2CC(C)(C)NC(C)(C)CC2=NN1C1CCCC1 GDKQBABXYRBLIR-UHFFFAOYSA-N 0.000 claims 1
- QJQVCIMYFOJBAG-UHFFFAOYSA-N 2-cyclopentyl-3-(4-fluorophenyl)-5-methyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CNC(C)CC(=C2C=3C=CC(F)=CC=3)C1=NN2C1CCCC1 QJQVCIMYFOJBAG-UHFFFAOYSA-N 0.000 claims 1
- WXXAEEWABMVOCW-UHFFFAOYSA-N 2-cyclopentyl-3-(4-fluorophenyl)-6-methyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C=1C=C(F)C=CC=1C1=C2CCN(C)CCC2=NN1C1CCCC1 WXXAEEWABMVOCW-UHFFFAOYSA-N 0.000 claims 1
- WWVMOFCTQXGOSL-UHFFFAOYSA-N 2-cyclopentyl-3-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(OC)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 WWVMOFCTQXGOSL-UHFFFAOYSA-N 0.000 claims 1
- VZHHRZTYWSUUQY-UHFFFAOYSA-N 2-cyclopentyl-3-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCC1 VZHHRZTYWSUUQY-UHFFFAOYSA-N 0.000 claims 1
- NGRITHKYYYAQAW-UHFFFAOYSA-N 2-cyclopentyl-5,5,7,7-tetramethyl-3-phenyl-6,8-dihydro-4h-pyrazolo[3,4-d]azepine Chemical compound C=1C=CC=CC=1C1=C2CC(C)(C)NC(C)(C)CC2=NN1C1CCCC1 NGRITHKYYYAQAW-UHFFFAOYSA-N 0.000 claims 1
- JXRCFWUSGNDEEG-UHFFFAOYSA-N 2-cyclopropyl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CC1N1C(C=2C=CC=CC=2)=C2CCNCCC2=N1 JXRCFWUSGNDEEG-UHFFFAOYSA-N 0.000 claims 1
- WOZMIJFBSUGNAA-UHFFFAOYSA-N 2-cyclopropyl-3-thiophen-3-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CC1N1C(C2=CSC=C2)=C2CCNCCC2=N1 WOZMIJFBSUGNAA-UHFFFAOYSA-N 0.000 claims 1
- KKTKOCXTKBKJND-UHFFFAOYSA-N 2-ethyl-3-(2-methylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=CC=C1C KKTKOCXTKBKJND-UHFFFAOYSA-N 0.000 claims 1
- PBQBRLIQOZTBLD-UHFFFAOYSA-N 2-ethyl-3-(4-ethylphenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(CC)=CC=C1C1=C(CCNCC2)C2=NN1CC PBQBRLIQOZTBLD-UHFFFAOYSA-N 0.000 claims 1
- NPWBKEMKWVXDFG-UHFFFAOYSA-N 2-ethyl-3-(4-fluorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=C(F)C=C1 NPWBKEMKWVXDFG-UHFFFAOYSA-N 0.000 claims 1
- WHWRBPFPNBNOLJ-UHFFFAOYSA-N 2-ethyl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=CS1 WHWRBPFPNBNOLJ-UHFFFAOYSA-N 0.000 claims 1
- GIGGCXZVWCJOCZ-UHFFFAOYSA-N 2-pentan-3-yl-3-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCC(CC)N1N=C2CCNCCC2=C1C1=CC=CC=C1 GIGGCXZVWCJOCZ-UHFFFAOYSA-N 0.000 claims 1
- NVYQGEKXZAORNX-UHFFFAOYSA-N 2-phenyl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C=12CCNCCC2=NN(C=2C=CC=CC=2)C=1C1=CC=CS1 NVYQGEKXZAORNX-UHFFFAOYSA-N 0.000 claims 1
- KCMAPBCUIWSGQN-UHFFFAOYSA-N 2-propan-2-yl-3-[4-(2h-tetrazol-5-yl)phenyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C(C=C1)=CC=C1C1=NN=NN1 KCMAPBCUIWSGQN-UHFFFAOYSA-N 0.000 claims 1
- DIIBWNCVXLXQDF-UHFFFAOYSA-N 2-propan-2-yl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=CS1 DIIBWNCVXLXQDF-UHFFFAOYSA-N 0.000 claims 1
- SXAVCXRTCOJISN-UHFFFAOYSA-N 2-tert-butyl-3-thiophen-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)(C)N1N=C2CCNCCC2=C1C1=CC=CS1 SXAVCXRTCOJISN-UHFFFAOYSA-N 0.000 claims 1
- PSMPKXOWQRPZLE-UHFFFAOYSA-N 2-tert-butyl-3-thiophen-3-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)(C)N1N=C2CCNCCC2=C1C=1C=CSC=1 PSMPKXOWQRPZLE-UHFFFAOYSA-N 0.000 claims 1
- NRMRRUUZGUSDCJ-UHFFFAOYSA-N 3-(1-benzyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2C=3CCNCCC=3N(CC=3C=CC=CC=3)N=2)=C1 NRMRRUUZGUSDCJ-UHFFFAOYSA-N 0.000 claims 1
- DIAIETRSPXZRRR-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1Cl DIAIETRSPXZRRR-UHFFFAOYSA-N 0.000 claims 1
- XICDOXXFWFXRIO-UHFFFAOYSA-N 3-(2-chlorophenyl)-2-ethyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=CC=C1Cl XICDOXXFWFXRIO-UHFFFAOYSA-N 0.000 claims 1
- IKEOANXGMKZZRK-UHFFFAOYSA-N 3-(2-chlorophenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=CC=C1Cl IKEOANXGMKZZRK-UHFFFAOYSA-N 0.000 claims 1
- LCPZAPQZDONCHF-UHFFFAOYSA-N 3-(2-methylphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=CC=C1C LCPZAPQZDONCHF-UHFFFAOYSA-N 0.000 claims 1
- INXVGDCDPUMLAG-UHFFFAOYSA-N 3-(3-chlorophenyl)-2-cyclohexyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound ClC1=CC=CC(C=2N(N=C3CCNCCC3=2)C2CCCCC2)=C1 INXVGDCDPUMLAG-UHFFFAOYSA-N 0.000 claims 1
- YJNLUNQLKMCRFT-UHFFFAOYSA-N 3-(3-chlorophenyl)-2-cyclopentyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound ClC1=CC=CC(C=2N(N=C3CCNCCC3=2)C2CCCC2)=C1 YJNLUNQLKMCRFT-UHFFFAOYSA-N 0.000 claims 1
- DEZIMNBAAODZEL-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-pentan-3-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCC(CC)N1N=C2CCNCCC2=C1C1=CC=CC(F)=C1 DEZIMNBAAODZEL-UHFFFAOYSA-N 0.000 claims 1
- VYJNBOKQYBMHPO-UHFFFAOYSA-N 3-(3-methylphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=CC(C)=C1 VYJNBOKQYBMHPO-UHFFFAOYSA-N 0.000 claims 1
- UIWBGBFTZRIVOF-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(2-methylpropyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=2CCNCCC=2N(CC(C)C)N=C1C1=CC=C(Cl)C=C1 UIWBGBFTZRIVOF-UHFFFAOYSA-N 0.000 claims 1
- LBJWBUATSAWLNP-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(2-phenylethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CCC1=CC=CC=C1 LBJWBUATSAWLNP-UHFFFAOYSA-N 0.000 claims 1
- FBMRISCWXQAUEK-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(4-methylcyclohexyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1CC(C)CCC1N1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 FBMRISCWXQAUEK-UHFFFAOYSA-N 0.000 claims 1
- XSLUDLWEZBOKLW-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(cyclohexylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1CCCCC1 XSLUDLWEZBOKLW-UHFFFAOYSA-N 0.000 claims 1
- FYZBJRYCQFCCHV-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(naphthalen-2-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=C(C=CC=C2)C2=C1 FYZBJRYCQFCCHV-UHFFFAOYSA-N 0.000 claims 1
- CZMDUKZPVVNQBY-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(oxan-4-yl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1C1CCOCC1 CZMDUKZPVVNQBY-UHFFFAOYSA-N 0.000 claims 1
- YJIXXEDMTYBTBY-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(pyridin-3-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CN=C1 YJIXXEDMTYBTBY-UHFFFAOYSA-N 0.000 claims 1
- IWPYOQHTXFMIRD-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(pyridin-4-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=NC=C1 IWPYOQHTXFMIRD-UHFFFAOYSA-N 0.000 claims 1
- DHIBKJMENXGCKF-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(thiophen-2-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CS1 DHIBKJMENXGCKF-UHFFFAOYSA-N 0.000 claims 1
- TWPDNZNHYQKPTO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2,4,6-trifluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC(F)=CC(F)=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 TWPDNZNHYQKPTO-UHFFFAOYSA-N 0.000 claims 1
- SLNWWYNQLZSUHK-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2,4-difluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC(F)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 SLNWWYNQLZSUHK-UHFFFAOYSA-N 0.000 claims 1
- IOWHEJZDXRUBOO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2,6-difluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC=CC(F)=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 IOWHEJZDXRUBOO-UHFFFAOYSA-N 0.000 claims 1
- UOUDOIMEQKEIJQ-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2,6-dimethylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC1=CC=CC(C)=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 UOUDOIMEQKEIJQ-UHFFFAOYSA-N 0.000 claims 1
- ASRPFSGUPWMNEE-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1Cl ASRPFSGUPWMNEE-UHFFFAOYSA-N 0.000 claims 1
- ZQPCPKCULXTIEJ-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-fluorophenyl)methyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound FC1=CC=CC=C1CN1C(CCNC2)=C2C(C=2C=CC(Cl)=CC=2)=C1 ZQPCPKCULXTIEJ-UHFFFAOYSA-N 0.000 claims 1
- PXJBCBNWSBPTRX-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-fluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 PXJBCBNWSBPTRX-UHFFFAOYSA-N 0.000 claims 1
- ZURPNBMDZUEIBI-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-methylphenyl)methyl]-4,5,6,7,8,9-hexahydropyrazolo[3,4-d]azocine Chemical compound CC1=CC=CC=C1CN1C(CCNCCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 ZURPNBMDZUEIBI-UHFFFAOYSA-N 0.000 claims 1
- LUFSUXFEHNKOFD-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-methylphenyl)methyl]-4,5,6,7,8,9-hexahydropyrazolo[4,3-d]azocine Chemical compound CC1=CC=CC=C1CN1C(CCCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 LUFSUXFEHNKOFD-UHFFFAOYSA-N 0.000 claims 1
- BFEIHVMKVIJYDO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(2-methylphenyl)methyl]-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine Chemical compound CC1=CC=CC=C1CN1C(CNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 BFEIHVMKVIJYDO-UHFFFAOYSA-N 0.000 claims 1
- PWPPVJHWMOLPSA-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3,4,5-trimethoxyphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound COC1=C(OC)C(OC)=CC(CN2C=3CCNCCC=3C(=N2)C=2C=CC(Cl)=CC=2)=C1 PWPPVJHWMOLPSA-UHFFFAOYSA-N 0.000 claims 1
- OSYXZOHVXOWZIH-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3,4-difluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(F)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 OSYXZOHVXOWZIH-UHFFFAOYSA-N 0.000 claims 1
- DLRZOJRYVXOTBM-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3,4-difluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[4,3-c]azepine Chemical compound C1=C(F)C(F)=CC=C1CN1C(CCCNC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 DLRZOJRYVXOTBM-UHFFFAOYSA-N 0.000 claims 1
- CFTXZTGBOFLZHR-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-chlorophenyl)methyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC(Cl)=C1 CFTXZTGBOFLZHR-UHFFFAOYSA-N 0.000 claims 1
- CIIRPRURJVUQJE-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-fluoro-4-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(OC)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 CIIRPRURJVUQJE-UHFFFAOYSA-N 0.000 claims 1
- SOZGSYXHOCVZPO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-fluoro-4-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(C)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 SOZGSYXHOCVZPO-UHFFFAOYSA-N 0.000 claims 1
- LMRIOLYVEJEYIS-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-fluoro-4-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[4,3-c]azepine Chemical compound C1=C(F)C(C)=CC=C1CN1C(CCCNC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 LMRIOLYVEJEYIS-UHFFFAOYSA-N 0.000 claims 1
- ROSNGOIGHNKLAY-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[4,3-c]azepine Chemical compound CC1=CC=CC(CN2C=3CCCNCC=3C(=N2)C=2C=CC(Cl)=CC=2)=C1 ROSNGOIGHNKLAY-UHFFFAOYSA-N 0.000 claims 1
- CESKRULBEWOHFI-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(3-nitrophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound [O-][N+](=O)C1=CC=CC(CN2C=3CCNCCC=3C(=N2)C=2C=CC(Cl)=CC=2)=C1 CESKRULBEWOHFI-UHFFFAOYSA-N 0.000 claims 1
- GCDWYDYIZUQGJW-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-chlorophenyl)methyl]-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1CN1C(CCNC2)=C2C(C=2C=CC(Cl)=CC=2)=C1 GCDWYDYIZUQGJW-UHFFFAOYSA-N 0.000 claims 1
- YDJUNJJOLXWHSK-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 YDJUNJJOLXWHSK-UHFFFAOYSA-N 0.000 claims 1
- MAEMLFWKSRDQNC-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[4,3-c]azepine Chemical compound C1=CC(Cl)=CC=C1CN1C(CCCNC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 MAEMLFWKSRDQNC-UHFFFAOYSA-N 0.000 claims 1
- FORTZCZRHXGHAU-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(OC)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 FORTZCZRHXGHAU-UHFFFAOYSA-N 0.000 claims 1
- NBVTTZRTMQNYCE-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 NBVTTZRTMQNYCE-UHFFFAOYSA-N 0.000 claims 1
- FDCBNFOBCFCQBU-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[4,3-c]azepine Chemical compound C1=CC(C)=CC=C1CN1C(CCCNC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 FDCBNFOBCFCQBU-UHFFFAOYSA-N 0.000 claims 1
- DSSZZQDKCFEYNZ-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[(4-nitrophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 DSSZZQDKCFEYNZ-UHFFFAOYSA-N 0.000 claims 1
- AJZZNOVTDCFKKH-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-cycloheptyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1C1CCCCCC1 AJZZNOVTDCFKKH-UHFFFAOYSA-N 0.000 claims 1
- QLHGNTNMHMXXHU-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-cyclooctyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1C1CCCCCCC1 QLHGNTNMHMXXHU-UHFFFAOYSA-N 0.000 claims 1
- IWSDFSHQHLGCGU-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=NN(C=2C=CC=CC=2)C2=C1CCNCC2 IWSDFSHQHLGCGU-UHFFFAOYSA-N 0.000 claims 1
- VXIQANFEDOSGOJ-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-prop-2-ynyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=NN(CC#C)C2=C1CCNCC2 VXIQANFEDOSGOJ-UHFFFAOYSA-N 0.000 claims 1
- DGISEZBEVOMWAA-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-propyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=2CCNCCC=2N(CCC)N=C1C1=CC=C(Cl)C=C1 DGISEZBEVOMWAA-UHFFFAOYSA-N 0.000 claims 1
- CJBVOTMPHJFLKI-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2-cyclohexylethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CCC1CCCCC1 CJBVOTMPHJFLKI-UHFFFAOYSA-N 0.000 claims 1
- UYQGFNFIDOBWPC-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2-methylpropyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)CN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 UYQGFNFIDOBWPC-UHFFFAOYSA-N 0.000 claims 1
- GTRPGHYMSGWGSO-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CCC1=CC=CC=C1 GTRPGHYMSGWGSO-UHFFFAOYSA-N 0.000 claims 1
- GSJWMMAUIVXLAQ-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(cyclohexylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CC1CCCCC1 GSJWMMAUIVXLAQ-UHFFFAOYSA-N 0.000 claims 1
- WCLLCJGPDBINKC-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(naphthalen-1-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CC1=CC=CC2=CC=CC=C12 WCLLCJGPDBINKC-UHFFFAOYSA-N 0.000 claims 1
- CKQDYLKSZPBTQS-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(thiophen-2-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1CC1=CC=CS1 CKQDYLKSZPBTQS-UHFFFAOYSA-N 0.000 claims 1
- XUBAIRBLYADLRA-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-[(2,4-difluorophenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC1=CC(F)=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 XUBAIRBLYADLRA-UHFFFAOYSA-N 0.000 claims 1
- ADFYQGRRLMMKMO-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-[(2-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound COC1=CC=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 ADFYQGRRLMMKMO-UHFFFAOYSA-N 0.000 claims 1
- OGUJPXKXEPAPFO-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-[(2-methylphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC1=CC=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 OGUJPXKXEPAPFO-UHFFFAOYSA-N 0.000 claims 1
- LZXHZOGFGYNRKO-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-[(3-fluoro-4-methoxyphenyl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=C(F)C(OC)=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 LZXHZOGFGYNRKO-UHFFFAOYSA-N 0.000 claims 1
- KMGWMEMAOCKHIA-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-[(5-chlorothiophen-2-yl)methyl]-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound S1C(Cl)=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 KMGWMEMAOCKHIA-UHFFFAOYSA-N 0.000 claims 1
- HLANKXFVKACZMS-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-cyclohexyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 HLANKXFVKACZMS-UHFFFAOYSA-N 0.000 claims 1
- FOGURHORAHCQMR-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-methyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 FOGURHORAHCQMR-UHFFFAOYSA-N 0.000 claims 1
- QFVCMXNGIBRGAL-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=C(CCNCC2)C2=NN1C1=CC=CC=C1 QFVCMXNGIBRGAL-UHFFFAOYSA-N 0.000 claims 1
- XSAFPPQZQQQNGU-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 XSAFPPQZQQQNGU-UHFFFAOYSA-N 0.000 claims 1
- VXHAACFBKZJOBB-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-propyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCCN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 VXHAACFBKZJOBB-UHFFFAOYSA-N 0.000 claims 1
- XMWQQZXHKVLBPU-UHFFFAOYSA-N 3-(4-chlorophenyl)-6-[(3,4-dimethoxyphenyl)methyl]-4,5,7,8-tetrahydro-1h-pyrazolo[3,4-d]azepine Chemical compound C1=C(OC)C(OC)=CC=C1CN1CCC(C(=NN2)C=3C=CC(Cl)=CC=3)=C2CC1 XMWQQZXHKVLBPU-UHFFFAOYSA-N 0.000 claims 1
- VGIHDQXDALKYBA-UHFFFAOYSA-N 3-(4-fluorophenyl)-2,6-di(propan-2-yl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C=12CCN(C(C)C)CCC2=NN(C(C)C)C=1C1=CC=C(F)C=C1 VGIHDQXDALKYBA-UHFFFAOYSA-N 0.000 claims 1
- NVPSINMDGWJDFN-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-pentan-3-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CCC(CC)N1N=C2CCNCCC2=C1C1=CC=C(F)C=C1 NVPSINMDGWJDFN-UHFFFAOYSA-N 0.000 claims 1
- ZDGOYPHIUFEMFW-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(F)=CC=C1C1=C(CCNCC2)C2=NN1C1=CC=CC=C1 ZDGOYPHIUFEMFW-UHFFFAOYSA-N 0.000 claims 1
- PNZUNOKRNYDVSC-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-propan-2-yl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine Chemical compound CC(C)N1N=C2CCNCC2=C1C1=CC=C(F)C=C1 PNZUNOKRNYDVSC-UHFFFAOYSA-N 0.000 claims 1
- PHZRFTGCEHPJBP-UHFFFAOYSA-N 3-(4-fluorophenyl)-4-methyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCC(C)C2=C1C1=CC=C(F)C=C1 PHZRFTGCEHPJBP-UHFFFAOYSA-N 0.000 claims 1
- KIEFUYJBPOOGIX-UHFFFAOYSA-N 3-(4-fluorophenyl)-5,5,7,7-tetramethyl-2-propan-2-yl-6,8-dihydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CC(C)(C)NC(C)(C)CC2=C1C1=CC=C(F)C=C1 KIEFUYJBPOOGIX-UHFFFAOYSA-N 0.000 claims 1
- NNHWFYTVMHNOSI-UHFFFAOYSA-N 3-(4-fluorophenyl)-5,7-dimethyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CC(C)NC(C)CC2=C1C1=CC=C(F)C=C1 NNHWFYTVMHNOSI-UHFFFAOYSA-N 0.000 claims 1
- NELMGJUBZMNTFN-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-methyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNC(C)CC2=C1C1=CC=C(F)C=C1 NELMGJUBZMNTFN-UHFFFAOYSA-N 0.000 claims 1
- RMZFPJHELIXCIM-UHFFFAOYSA-N 3-(4-fluorophenyl)-6-(2-phenylethyl)-2-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CC2=C(C=3C=CC(F)=CC=3)N(C(C)C)N=C2CCN1CCC1=CC=CC=C1 RMZFPJHELIXCIM-UHFFFAOYSA-N 0.000 claims 1
- UBFMEBGDILYQHG-UHFFFAOYSA-N 3-(4-fluorophenyl)-6-methyl-2-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCN(C)CCC2=C1C1=CC=C(F)C=C1 UBFMEBGDILYQHG-UHFFFAOYSA-N 0.000 claims 1
- RMAUODJMJBIZSM-UHFFFAOYSA-N 3-(4-fluorophenyl)-7-methyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CC(C)NCCC2=C1C1=CC=C(F)C=C1 RMAUODJMJBIZSM-UHFFFAOYSA-N 0.000 claims 1
- HFAGGJZWKFFGLM-UHFFFAOYSA-N 3-(4-methoxyphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(OC)=CC=C1C1=C(CCNCC2)C2=NN1C(C)C HFAGGJZWKFFGLM-UHFFFAOYSA-N 0.000 claims 1
- XGWNBESKWRZUPF-UHFFFAOYSA-N 3-(4-methylphenyl)-2-phenyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(C)=CC=C1C1=C(CCNCC2)C2=NN1C1=CC=CC=C1 XGWNBESKWRZUPF-UHFFFAOYSA-N 0.000 claims 1
- CSMRYJUSHGBKRF-UHFFFAOYSA-N 3-(4-nitrophenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C([N+]([O-])=O)C=C1 CSMRYJUSHGBKRF-UHFFFAOYSA-N 0.000 claims 1
- NSXOQTDOJSFHML-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=C(C(C)(C)C)C=C1 NSXOQTDOJSFHML-UHFFFAOYSA-N 0.000 claims 1
- RMZCCKLYFJXOJV-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)phenyl]-2-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound FC(F)(F)CN1N=C2CCNCCC2=C1C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 RMZCCKLYFJXOJV-UHFFFAOYSA-N 0.000 claims 1
- FYUFQFDXEFUQOQ-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)phenyl]-2-cyclopentyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C=2N(N=C3CCNCCC3=2)C2CCCC2)C=C1 FYUFQFDXEFUQOQ-UHFFFAOYSA-N 0.000 claims 1
- XTSUEZJHVHDKGO-UHFFFAOYSA-N 3-phenyl-2-propan-2-yl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine Chemical compound CC(C)N1N=C2CNCCC2=C1C1=CC=CC=C1 XTSUEZJHVHDKGO-UHFFFAOYSA-N 0.000 claims 1
- BYRBLSMXVKIFRV-UHFFFAOYSA-N 3-phenyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CCNCCC2=C1C1=CC=CC=C1 BYRBLSMXVKIFRV-UHFFFAOYSA-N 0.000 claims 1
- AGJAGXXZXFGUAZ-UHFFFAOYSA-N 4-(1-benzyl-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-3-yl)phenol Chemical compound C1=CC(O)=CC=C1C(C=1CNCCC=11)=CN1CC1=CC=CC=C1 AGJAGXXZXFGUAZ-UHFFFAOYSA-N 0.000 claims 1
- FGPSVUCVCSPAMT-UHFFFAOYSA-N 4-(1-benzyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC=C1 FGPSVUCVCSPAMT-UHFFFAOYSA-N 0.000 claims 1
- FBKXNSQPDRMCGH-UHFFFAOYSA-N 4-(2-cyclohexyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=C(CCNCC2)C2=NN1C1CCCCC1 FBKXNSQPDRMCGH-UHFFFAOYSA-N 0.000 claims 1
- SEZXJGNYSGEPLS-UHFFFAOYSA-N 4-(2-cyclopropyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=C(CCNCC2)C2=NN1C1CC1 SEZXJGNYSGEPLS-UHFFFAOYSA-N 0.000 claims 1
- CFPVZGDZCAYDLJ-UHFFFAOYSA-N 4-(2-ethyl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-3-yl)benzonitrile Chemical compound CCN1N=C2CCNCCC2=C1C1=CC=C(C#N)C=C1 CFPVZGDZCAYDLJ-UHFFFAOYSA-N 0.000 claims 1
- NOOMNSDHDFCWKL-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]butanoic acid Chemical compound C1=2CCNCCC=2N(CCCC(=O)O)N=C1C1=CC=C(Cl)C=C1 NOOMNSDHDFCWKL-UHFFFAOYSA-N 0.000 claims 1
- BJTUNMMAKOKRFG-UHFFFAOYSA-N 4-[[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl]methyl]-2-fluorophenol Chemical compound C1=C(F)C(O)=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 BJTUNMMAKOKRFG-UHFFFAOYSA-N 0.000 claims 1
- FPWNLURCHDRMHC-UHFFFAOYSA-N 4-chlorobiphenyl Chemical group C1=CC(Cl)=CC=C1C1=CC=CC=C1 FPWNLURCHDRMHC-UHFFFAOYSA-N 0.000 claims 1
- CHKDVLNFSJAPNF-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl]pentanoic acid Chemical compound OC(=O)CCCCN1N=C2CCNCCC2=C1C1=CC=C(Cl)C=C1 CHKDVLNFSJAPNF-UHFFFAOYSA-N 0.000 claims 1
- FOYOEAUZRWEGOA-UHFFFAOYSA-N 6-benzyl-2-propan-2-yl-3-thiophen-3-yl-5,7-dihydro-4h-pyrazolo[3,4-c]pyridine Chemical compound C1CC2=C(C3=CSC=C3)N(C(C)C)N=C2CN1CC1=CC=CC=C1 FOYOEAUZRWEGOA-UHFFFAOYSA-N 0.000 claims 1
- WTTFELSUJGSCSB-UHFFFAOYSA-N 6-benzyl-3-(4-fluorophenyl)-2-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CC2=C(C=3C=CC(F)=CC=3)N(C(C)C)N=C2CCN1CC1=CC=CC=C1 WTTFELSUJGSCSB-UHFFFAOYSA-N 0.000 claims 1
- TZGAENDODQBDHL-UHFFFAOYSA-N 6-benzyl-3-(4-fluorophenyl)-2-propan-2-yl-5,7-dihydro-4h-pyrazolo[3,4-c]pyridine Chemical compound C1CC2=C(C=3C=CC(F)=CC=3)N(C(C)C)N=C2CN1CC1=CC=CC=C1 TZGAENDODQBDHL-UHFFFAOYSA-N 0.000 claims 1
- KLRPPWWXISTWBW-UHFFFAOYSA-N 6-benzyl-3-(4-fluorophenyl)-8-methyl-2-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C1CC2=C(C=3C=CC(F)=CC=3)N(C(C)C)N=C2C(C)CN1CC1=CC=CC=C1 KLRPPWWXISTWBW-UHFFFAOYSA-N 0.000 claims 1
- VVUAEJHYYBTRFA-UHFFFAOYSA-N 6-methyl-2,3-diphenyl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine Chemical compound C=12CCN(C)CCC2=NN(C=2C=CC=CC=2)C=1C1=CC=CC=C1 VVUAEJHYYBTRFA-UHFFFAOYSA-N 0.000 claims 1
- HSFQLELKSBFMKV-UHFFFAOYSA-N 7-methyl-3-(4-methylphenyl)-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CC(C)NCCC2=C1C1=CC=C(C)C=C1 HSFQLELKSBFMKV-UHFFFAOYSA-N 0.000 claims 1
- LQLNUPNZJRFAFT-UHFFFAOYSA-N 7-methyl-3-phenyl-2-propan-2-yl-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound CC(C)N1N=C2CC(C)NCCC2=C1C1=CC=CC=C1 LQLNUPNZJRFAFT-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 101100385396 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cka1 gene Proteins 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- LHZAPEGWVNPJRD-UHFFFAOYSA-N azulene;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound C1=CC=CC2=CC=CC2=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O LHZAPEGWVNPJRD-UHFFFAOYSA-N 0.000 claims 1
- 150000001545 azulenes Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- CELDKMHGHKIPMR-UHFFFAOYSA-N ethyl 5-[[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-2-yl]methyl]furan-2-carboxylate Chemical compound O1C(C(=O)OCC)=CC=C1CN1C(C=2C=CC(Cl)=CC=2)=C2CCNCCC2=N1 CELDKMHGHKIPMR-UHFFFAOYSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- AFGXXQVAUXGYIN-UHFFFAOYSA-N methyl 2-[1-benzyl-3-(4-chlorophenyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azepin-6-yl]acetate Chemical compound C1CN(CC(=O)OC)CCC(C(=N2)C=3C=CC(Cl)=CC=3)=C1N2CC1=CC=CC=C1 AFGXXQVAUXGYIN-UHFFFAOYSA-N 0.000 claims 1
- BMFAXTLZTXUOMW-UHFFFAOYSA-N methyl 2-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]acetate Chemical compound C1=2CCNCCC=2N(CC(=O)OC)N=C1C1=CC=C(Cl)C=C1 BMFAXTLZTXUOMW-UHFFFAOYSA-N 0.000 claims 1
- RQVAXDBLDPZEML-UHFFFAOYSA-N methyl 4-[[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(CCNCC2)=C2C(C=2C=CC(Cl)=CC=2)=N1 RQVAXDBLDPZEML-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- NNHXRIRECZBUAL-UHFFFAOYSA-N tert-butyl 3-(4-fluorophenyl)-2-propan-2-yl-4,5,7,8-tetrahydropyrazolo[3,4-d]azepine-6-carboxylate Chemical compound CC(C)N1N=C2CCN(C(=O)OC(C)(C)C)CCC2=C1C1=CC=C(F)C=C1 NNHXRIRECZBUAL-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000011575 calcium Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- GLDOEZLYGFSSQI-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(naphthalen-1-ylmethyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepine Chemical compound C1=CC(Cl)=CC=C1C(C=1CCNCCC=11)=NN1CC1=CC=CC2=CC=CC=C12 GLDOEZLYGFSSQI-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- HSFGLHOBOIVATH-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]butan-1-ol Chemical compound C1=2CCNCCC=2N(CCCCO)N=C1C1=CC=C(Cl)C=C1 HSFGLHOBOIVATH-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- UZRATJRWDKFMAO-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4h-pyrazolo[3,4-d]azepin-1-yl]pentanoic acid Chemical compound C1=2CCNCCC=2N(CCCCC(=O)O)N=C1C1=CC=C(Cl)C=C1 UZRATJRWDKFMAO-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000004965 Hartree-Fock calculation Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010065508 Orthostatic hypertension Diseases 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
FUSED HETEROCYCLIC COMPOUNDS
There is provided by the present invention compounds that are serotonin receptor modulators. More particularly, there is provided by the present invention fused heterocyclic compounds that are serotonin receptor modulators useful for the treatment of disease states mediated by serotonin receptor activity.
Serotonin (5-hydroxytryptamine, 5-HT) is a major neurotransmitter eliciting effects via a multiplicity of receptors. To date, at least fifteen different 5-HT receptors have been identified, largely as the result of cloning cDNA’s, and these receptors have been grouped into seven families (5-HT, through 5-
HT) (Hoyer, D. et al. Pharmacol. Biochem. Behav. (2002) 71, 533-554).
Fourteen of the fifteen cloned 5-HT receptors are expressed in the brain. 5-HT is implicated in many disease states, particularly conditions of the central nervous system including; depression, anxiety, schizophrenia, eating disorders, obsessive compulsive disorder, learning and memory dysfunction, migraine, chronic pain, sensory perception, motor activity, temperature regulation, nociception, sexual behavior, hormone secretion and cognition. The identification of multiple 5-HT receptors has provided the opportunity to characterize existing therapeutic agents thought to act via the serotonergic system. Consequently, this has led to the realization that many drugs have non-selective properties (Roth, B.L. et al. Neuroscientist (2000) 6(4) 252-262).
For example, the antipsychotic drugs, clozapine, chlorpromazine, haloperidol and olanzapine exhibit affinities for multiple serotonin receptors in addition to other families of receptors. Similar behavior has been noted for antidepressants, including imipramine, nortriptaline, fluoxetine and sertraline.
Similarly, the anti-migraine agent sumatriptan exhibits high affinity for several serotonin receptors. While the lack of selectivity often contributes to a favorable therapeutic outcome, it can also cause undesirable and dose-limiting side effects (Stahl, S.M. Essential Psychopharmacology, 2™ ed., Cambridge
University Press, Cambridge, U.K., 2000). Thus, the inhibition of serotonin and norepinephrine uptake together with 5-HT. receptor blockade is responsible for the therapeutic effects of the tricyclic antidepressants. In contrast, their blockade of histamine Hs, muscarinic and alpha-adrenergic receptors can lead to sedation, blurred vision and orthostatic hypertension respectively. Likewise, the atypical antipsychotics, including olanzapine and clozapine, are considered to have positive therapeutic effects attributable to their actions at 5-HTz, D2 and 5-HT; receptors. Conversely, their side effect liability is due to their affinities at a range of dopaminergic, serotonergic and adrenergic receptors.
More selective ligands therefore have the potential to ameliorate untoward pharmacologies and provide novel therapies. More importantly the ability to obtain compounds with known receptor selectivities affords the prospect to target muitiple therapeutic mechanisms and improve clinical responses with a single drug.
The invention features a compound of formulae (1), (1) and (111):
R? CYCHALK)q
CYC-ALK GN SA YOANN Ar 'e ) — y= a Sr SR a
Tw RN "hw (I) (I) (1) wherein mis0,1o0r2 nis1,2or3; pis 1, 2 or 3, with the proviso that where mis 1, pis not 1; m+n is less than or equal to 4; m+p is less than or equal to 4; qisOort; ris0, 1,2, 3, 4,05;
R® is -C1aalkyl, allyl, propargyl, or benzyl, each optionally substituted with -C.salkyl, “OH, or halo;
Ar is an aryl or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R' or di-substituted on adjacent carbons with -OC1.4alkyleneO-, -(CHz)2.3NH-, -(CHz)1.2NH(CHo)-, (CH2)2.9N(C1.salkyl)- or -(CH2)1.2N(C1.salkyl)(CHz)-;
R' is selected from the group consisting of —OH, -C1-salkyl, -OC.salkyl, -C2.salkenyl, -OCagalkenyl, -Cz.galkynyl, -OCa alkynyl, -CN, -NO., -N(R*)R* (wherein RY and R* are independently selected from H or Cq_salkyl), -(C=O)N(R")R?, -(N-R)COR!, -(N-RYSO2Cy-ealkyl (wherein R'is H or Cs.ealkyl), -(C=0)C;.¢alkyl, -(S=(O)n)-C1-s2lkyl (wherein n is selected from 0, 1 or 2), -SO.N(R")R?, -SCFs3, halo, -CFs, -OCFs, -COOH and -COOCgalkyl; b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered ! aromatic ring, which moiety has one carbon atom replaced by >0, >S, >NH or >N(C1.salkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R'; c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R’; d) naphthyl, optionally mono-, di- or tri-substituted with R’; e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C1.salkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R'; and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- of di-substituted with R* and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R" g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R';
ALK is a branched or unbranched Cs.salkylene, C..salkenylene, Cosalkynylene or Cascycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC4 alkyl, -OCascycloalkyl, -CN, -NO, -N(R*R® (wherein R* and R® are independently selected from H, C1.alkyl or Cz.ealkenyl), (C=O)N(R*R", -(N-R)COR®, -(N-R)SO.C, alkyl (wherein RC is H or Cy.salkyl), -(C=0)C.¢alkyl, -(S=(0)s)-C1-salkyl (wherein d is selected from 0, 1 or 2), -SO,N(R®)R®, -SCFs3, halo, -CF3, -OCF3, -COOH and -COOCgalkyl,
CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -OC+.4alkyleneO-, -(CHg)2.aNH-, -(CHa)1.2NH(CHz)-, -(CHz)23N(C1.salkyl)- or -(CHz)12N(C1-4alkyl)(CHz)-;
RY is selected from the group consisting of OH, -C1.salkyl, : -OC;.salkyl, -Cascycloalkyl, -OCsecycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO, -N(R*)R" (wherein R" and RP are independently selected from H, Cy.salkyl or C2.¢alkenyl, or R® and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O,
=N-, >NH or >N(C.salkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R*)R”, -(N-R°)COR’, -(N-R%)SO:C1.calkyl (wherein R® is H or Cs.calkyl or two R® in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO2C1.calkyl)z, -(C=0)C.salkyl, -(S=(0)q4)-Cr-salkyl (wherein d is selected from 0, 1 or 2), -SON(R?)R®, -SCFs, halo, -CFs, -OCFs, -COOH and
-COOCgalkyl;
ii) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(C1«alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY; iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;
iv) naphthyl, optionally mono-, di- or tri-substituted with RY v) a monocyclic aromatic hydrocarbon group having five ring atoms, : having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C;.4alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R? and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R%;
vi) a monocyclic aromatic hydrocarbon group having six ring atoms,
having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with RY; vii) a 3-8 membered non-aromatic carbocyclic of heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 t0 5 substituents RY and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R%; and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RY;
R' is selected from the group consisting of H, C.7alkyl, Co7alkenyl, Co7alkynyl,
Ca.7cycloalkyl, CazcycloalkylCi.7alkyl, Ca scycloalkenyl,
Ca7cycloalkenylCy.7alkyl and benzo-fusedCa.7cycloalkyl, each optionally mono-, di-, or tri-substituted with RP;
RP is selected from the group consisting of —OH, -OC4 alkyl, -Caecycloalkyl, -OCa.cycloalkyl, -CN, -NOz, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®)R" (wherein R® and R" are independently selected from H or Cysalkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C4-alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R*)R", -(N-R¥)CORY, -(N-R")SO:C.¢alkyl (wherein R' is H or Cy.¢alkyl or two
RY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C1.salkyl, -(S=(0)n)-C1-galkyl (wherein n is selected from 0, 1 or 2), -SON(R®)R", -SCF3, halo, -CF3, -OCF;3, -COOH and -COOC;.salkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: OH, -Ci.salkyl, -OC1.ealkyl, -CN, -NO., N(R®)R" (wherein R® and R® are independently selected from H, C1.salkyl or
Cz-salkenyl), -(C=O)N(R®R", -(N-R°)COR?®, -(N-R°)SO2C1-salkyl (wherein R® is H or C1.¢alkyl), -(C=0)C1.galkyl, -(S=(0)q)-C1-salkyl (wherein d is selected from 0, 1 or 2), -SO.N(RYR", -SCF3, halo, -CF,, -OCF3, -COOH and -COOC, ¢alkyl;
R? is selected from the group consisting of H, Cy.7alkyl, C..zalkenyl, Co.7alkynyl and Ca.rcycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.
Similarly, isomeric forms of the compounds of formulae (n, (11), and (I), and of their pharmaceutically acceptable salts, esters, and amides, are encompassed within the present invention, and reference herein to one of such isomeric forms is meant to refer to at least one of such isomeric forms. One of ordinary skill in the art will recognize that compounds according to this invention may exist, for example in a single isomeric form whereas other compounds may exist in the form of a regioisomeric mixture.
The invention also features pharmaceutical compositions containing such compounds and methods of using such compositions in the treatment or prevention of disease states mediated by the serotonin receptors, particularly, 5-HT; and/or 5-HT; receptor subtypes.
Preferably, mis 1 or 2 and most preferably, mis 1.
Preferably, nis 1 or 2.
Preferably, pis 1 or 2.
Preferably, m+n is 2 or 3.
Preferably, m+p is 2 or 3.
Preferably, gis 1. :
Preferably, ris 0, 1, or 2.
Preferably, ris 4.
Preferably R®, optionally substituted, is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, allyl, propargyl, and benzyl.
Preferably, R® is methyl.
Preferably Ar, optionally substituted, is selected from the group consisting of: a) phenyl, 5-, 6-, 7-, 8-benzo-1,4-dioxanyl, 4-, 5-, 6-, 7-benzo-1,3- dioxolyl, 4-, 5-, 6-, 7-indolinyl, 4-, 5-, 6-, 7-isoindolinyl, 1,2,3,4-tetrahydro- . 15 quinolin-4, 5, 6 or 7-yl, 1,2,3,4-tetrahydro-isoquinolin-4, 5, 6 or 7-yl, b) 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1,2-alpyridin-5, 6, 7 or 8- yl, pyrazolo[1,5-alpyridin-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, c) 5-, 6-, 7- or 8-isoquinolinyl, 5-, 6-, 7- or 8-quinolinyl, 5-, 6-, 7- or 8- quinoxalinyl, 5-, 6-, 7- or 8-quinazolinyl, d) naphthyl, e) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2- benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indoiyl, 2- benzthiazolyl, 2-benzimidazolyl, 3-indazolyl, f) pyridinyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, 1-, 3- or 4-isoquinolinyl, 2-, 3- or 4-quinolinyl, 2- or 3-quinoxalinyl, 2- or 4-quinazolinyl, [1,5], [1,6], [1,7], or [1,8]naphthyridin-2-, 3-, or 4-yl, [2,5], [2.6], [2,7], [2,8]naphthyridin-1-, 3-, or 4-yl, and g) biphenyl, 4-tetrazolylphenyl.
More preferably, Ar, optionally substituted, is selected from the group consisting of phenyl, pyridyl, thiophen-2-yl and thiophen-3-yl.
Specific Ar may be selected from the group consisting of phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-ethyiphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chloropheny!, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyt, 2-trifluoromethyiphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 3-acetylphenyl, 4-acetylphenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyt, 2,4-dichlorophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-chloro-4-fluorophenyl, 3-fluoro-4-chlorophenyi, benzo[1,3]dioxol-4 or 5-yl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-hydroxy-2- methylphenyl, 4-hydroxy-3-fluorophenyl, 3,4-dihydroxyphenyl,4- dimethylaminophenyl, 4-carbamoylphenyl, 4-fluoro-3-methylphenyl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, 5-chlorothiophen-2-yl, 5- methylthiophen-2-yl, 5-chlorothiophen-3-yi, 5-methylthiophen-3-yl, 4'- chiorobiphenyl, and 4-tetrazolyiphenyl.
Preferably, ALK, optionally substituted, is selected from the group consisting of methylene, ethylene, propylene, butylene, tert-butylene, pentylene, 1-ethylpropylene, 2-ethylpropylene, 2-ethylbutylene, isopropylene, but-3-enylene, isobutylene, 3-methylbutylene, allylene, and prop-2-ynylene.
Specific ALK may be selected from the group consisting of methylene, trifluoromethylmethylene, methoxycarbonylmethyl, methylcarbamoylmethyl, ethylene, propylene, 3-methoxycarbonyl propylene, 3-carboxy propylene, butylene, tert-butylene, 4-hydroxybutylene, 4-methoxycarbonyl butylene, 4- carboxy butylene, pentylene, 5-hydroxypentylene, 1-ethylpropylene, 2- ethylpropylene, 2-ethylbutylene, isopropylene, but-3-enylene, isobutylene, 3- methylbutylene, prop-2-ynylene, 2-dimethylaminoethylene, and 2- cyanoethylene.
Preferably CYC, optionally substituted, is hydrogen or is selected from the group consisting of:
i) phenyl, 5-, 6-, 7-, 8-benzo-1 ,4-dioxanyl, 4-, 5-, 6-, 7-benzo-1,3-dioxolyl, 4-, 5. 6-, 7-indolinyl, 4-, 5-, 6-, 7-isoindolinyl, 1,2,3,4-tetrahydro-quinolin-4, 5, 6 or 7-yl, 1,2,3,4-tetrahydro-isoquinolin-4, 5, 6 or 7-yl, ii) 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1 ,2-a)pyridin-5, 6, 7 or 8- yl, pyrazolo[1,5-a]pyridin-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-y, iii) 5-, 6-, 7- or 8-isoquinolinyl, 5-, 6-, 7- or 8-quinolinyl, 5-, 6-, 7- or 8- quinoxalinyl, 5-, 6-, 7- or 8-quinazolinyl, iv) naphthyl, v) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyi, pyrroiyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2- benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indolyl, 2- benzthiazolyl, 2-benzimidazolyl, 3-indazolyl, vi) pyridinyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, 1-, 3- or 4-isoquinolinyl, 2-, 3- or 4-quinolinyl, 2- or 3-quinoxalinyl, 2- or 4-quinazolinyl, [1,5], [1,6], [1,7], or [1,8]naphthyridin-2-, 3-, or 4-yl, [2,5], [2,6], [2,7), [2,8]naphthyridin-1-, 3-, or 4-yl, vii) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, ~ cycloheptyl, cyclooctyl, adamantyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, piperidinyl, homopiperidinyl, azepanyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinonyl, indanyl, dihydroindolyl, oxindolyl, dihydropyrrolopyridinyl, and viii) bicyclo[4.1 .0Jheptane, octahydroindolyl, octahydroisoindolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydropyrrolopyridinyl, and octahydropyrrolopyrrolidinyl.
More preferably, CYC, optionally substituted, is selected from the group consisting of hydrogen, phenyl, indolyl, benzthiazolyl, isoquinolyl, quinazolinyl, naphthalen-1 or 2-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yi, furan-3-yi, pyridinyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, piperidin-
2,3 or 4-yl, 2-pyrrolin-2, 3, 4 or 5-yl, 3-pyrrolin-2 or 3-yl, 2-pyrazolin-3, 4 or 5-yi, morpholin-2, 3, 5 or 6-yl, thiomorpholin-2, 3, 5 or 6-yl, piperazin-2, 3, 5 or 6-yl, pyrrolidin-2 or 3-yl, homopiperidinyl, adamantanyl, and octahydroindoiyl.
Most preferably, CYC, optionally substituted, is selected from the group consisting of hydrogen, phenyl, pyridyl, cyclobutyl, cyclopentyl, cyclohexyl, thiophen-2-yl, thiophen-3-yl, tetrahydropyranyl, furan-2-yl, furan-3-yl and naphthalen-1 or 2-yl.
Specific CYC may be selected from the group consisting of hydrogen, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methyliphenyl, 3-methylphenyl, 4-methyiphenyl, 4-ethylphenyl, 2-chlorophenyi, 3-chlorophenyi, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyi, 4A-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-acetylphenyl, 4-acetylphenyl, 3,4-difluorophenyl, 3,4-dichiorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyi, 2,6-dimethylphenyl, 2,4 6-trifluorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trimethoxyphenyl, cyclobutyl, cyclohexyl, cyclopentyl, 4-fluoro-3-methylphenyl, 3-nitrophenyl, 4-nitrophenyl, 4-methyl-3-fluorophenyl, 3,4-dimethylphenyl, 4-methoxy-3-fluorophenyl, 4- methoxy-2-methylphenyl, 3-aminophenyl, 4-aminophenyl, 4- carbomethoxyphenyl, 3-methanesulfonylamino-phenyl, 4-methanesulfonylamino-phenyl, 3-dimethanesulfonylamino-phenyi, y 4-dimethanesulfonylamino-phenyl, thiophen-2-yl, thiophen-3-yl, 5- chlorothiophen-2-yl, benzo[1,3]dioxol-4 or 5-yl, tetrahydropyran-2,3 or 4-yl, furan-2-yl, furan-3-yl, 5-carboxyethyl-furan-2-yl, naphthalen-1 or 2-yl, 3,4- bisbenzyloxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-hydroxy-2-methyliphenyl, 4-hydroxy-3-fluorophenyl and 3,4-dihydroxyphenyl.
Preferably, R' is selected from the group consisting of hydrogen,
Ci-zalkyl, Cosalkenyl, Cogalkynyl, Caecycloalkyl, CascycloalkylC,.aalkyl,
Cs-scycloalkenyl, benzo-fusedCs ecycloalkyl, each optionally mono-, di-, or tri- substituted with R®.
More preferably, R', optionally RP substituted, is selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.
Specific R'-may be selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 3-hydroxypropyl, benzyl, 3,4-dimethoxybenzyl, methoxycarbonylmethyl, carbamoyimethyl, phenethyl, phenpropyl, and hydroxyethyl.
Preferably, R? is hydrogen, Cq.salkyl, Czalkenyl, C.4alkynyl, or
Caecycloalkyl.
More preferably, R? is hydrogen or methyl. lt is understood that some compounds referred to herein are chiral and/or have geometric isomeric centers, for example E- and Z- isomers. The present invention encompasses all such optical, including stereoisomers and racemic mixtures, diastereomers, and geometric isomers that possess the activity that characterizes the compounds of this invention. In addition, certain compounds referred to herein can exist in solvated as well as unsolvated forms. It is understood that this invention encompasses all such solvated and unsolvated forms that possess the activity that characterizes the compounds of this invention. :
Compounds according to the present invention that have been modified to be detectable by some analytic technique are also within the scope of this invention. The compounds of the present invention may be labeled with radioactive elements such as '%°1, *F, ''C, Cu, and the like for use in imaging or for radioactive treatment of patients. An example of such compounds is an isotopically labeled compound, such as an '8F isotopically labeled compound that may be used as a probe in detection and/or imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Preferably, compounds of the present invention labeled with 'F or *'C may be used as a positron emission tomography (PET) molecular probe for studying serotonin-mediated disorders. Another example of such compounds is an isotopically labeled compound, such as a deuterium and/or tritium labeled compound that may be used in reaction kinetic studies.
The compounds described herein may be reacted with an appropriate functionalized radioactive reagents using conventional chemistry to provide radiolabeled compounds.
Pharmaceutically acceptable salts, esters, and amides include carboxylate salts (e.g., Ci.salkyl, Ca.sCycloalkyl, aryl, C..1oheteroaryl, or Cz-10 non-aromatic heterocyclic), amino addition salts, acid addition salts, esters, and amides that are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative addition salts for compounds of formula (1) displaying basic functionality include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. Representative addition salts for compounds of formula (1) displaying acidic functionality are those that form non-toxic base salts with such compounds. These salts may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See example, S.M. Berge, et al., “Pharmaceutical Salts,” J.
Pharm. Sci., 1977, 66:1-19, which is incorporated herein by reference.
Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary Ci. alkyl amines and secondary di(C,.salkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C1.salkyl primary amines, and di(C1.calkyl)amines.
Representative pharmaceutically acceptable esters of the invention include
C1.7alkyl, Cs.scycloalkyl, phenyl, and phenyl(C1.e)alkyl esters. Preferred esters include methyl esters.
Preferred compounds, which are fused pyrroles, are selected from the group consisting of:
x omewoanwe 1 “Benzyl-3-(4-nitro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- 1 “Benzyl-3-(3-chloro-4-fluoro-phenyl)-4,5,6,7-tetrahydro-1 H- 2 | pyrrolo[3,2-cjpyridine; 1 “Benzyl-3-(4-trifluoromethoxy-phenyl)-4,5,6,7-tetrahydro-1 H 1 “Benzy!-3-(5-chioro-thiophen-2-yl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-
Lo
Ut Cl a clpyridine; 1-Benzyl-3-(3-fluoro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolof3,2- 3-(4-Chloro-phenyl)-1 -(2-fluoro-benzyl)-4,5,6,7-tetrahydro-1H-
Rl ei pyrrolo[3,2-c]pyridine; cJpyridine, pyrrolo[3,2-cjpyridine; clpyridine; . clpyridine; pyrrolo[3,2-c]pyridine; 1-(2,4-Dichloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-
ET
1 “Benzyl-2-methyl-3-phenyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- 1-Be nzyl-3-(3,4-dichloro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; 3-Benzo[1,3)dioxol-5-yl-1-be nzyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine,; cJpyridine; pyrrolof3,2-clpyridine; cJpyridine;
I I a i ds cJpyridine; 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahyd ro-pyrrolo[2,3-
EE
1-Benzyl-3-(5-chloro-thiophen-2-yl)-1 .4,5,6,7,8-hexahydro-pyrrolof2,3-
EE
1-(4-Chloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-
EE dlazepine; 1-Benzyl-3-(3-chloro-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-
EB c)pyridine; cJpyridine;
1 “Benzyl-3-(a-chioro-phenyl)-5-ethyl-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-clpyridine; 1-Benzyl-3-(4-chioro-phenyl)-5-isopropyl-4,5,6,7-tetrahydro-1H- 3-[1-Benzyl-3-(4-chloro-phenyl)-1 4.6,7-tetrahydro-pyrrolo[3,2- 1 ~Benzyl-3-(4-chloro-phenyl)-5-methyl-4,5,6,7-tetrahydro-1 H 1-Benzyl-3-(3-chloro-phenyl)-5-methyl-4,5,6,7-tetrahydro-1 H- 1 -Benzyl-3-(3-chioro-4-fluoro-phenyi)-5-methyl-4,5,6,7-tetrahydro-1 H
El : and . 1-Benzyl-5-isopropyl-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-
ET
Preferred compounds, which are fused 1-substituted pyrazoles, are selected from the group consisting of: triaza-azulene; azulene, 1-Benzyl-3-(3-fluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- [TE azulene; 1-Benzyl-3-(2,3-difluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza-
1 “Benzyl-3-(3,4-dichloro-phenyl)-1 4,5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 1-[4-(1-Benzyl-1,4,5,6,7,8-hexahydro-1 2 6-triaza-azulen-3-yl)- 1-Benzyl-3-(4-trifluoromethoxy-phenyl)-1 4.5,6,7,8-hexahydro-1,2,6- 1-Benzyl-3-(3-chloro-phenyl)-1 4.5 6,7,8-hexahydro-1,2,6-triaza- — 3-(1-Benzyl-1,4,5,6,7,8-hexahydro-1 .2,6-triaza-azulen-3-yl)- 4-(1-Benzyl-1,4,5,6,7,8-hexahydro-1 2,6-triaza-azulen-3-yl)- — 1-(4-Chloro-benzyl)-3-phenyl-1 ,4,5,6,7,8-hexahydro-1,2,6-triaza- 1-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1 ,4,5,6,7,8-hexahydro- vr azulene, 1-Benzyl-6-isopropyl-3-phenyi-1 4,5,6,7,8-hexahydro-1 ,2,6-triaza- 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- eT 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1 ,2,5-triaza- ro | EE azulene; 3-(4-Chloro-phenyl)-1-ethyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- [Lo | TEmm———__— 3-(4-Chloro-phenyl)-1-propyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- oo | TE fa azulene;,
3-(4-Chloro-phenyl)-1 -(2-cyclohexyl-ethyl)-1 4,5,6,7,8-hexahydro- a 3-(4-Chloro-phenyl)-1 -phenethyl-1 4.5,6,7,8-hexahydro-1,2,6-triaza- 3-(4-Chloro-phenyl)-1 -(4-fluoro-3-methyl-benzyl)-1 ,4,5,6,7,8- 3-(4-Chioro-phenyl)-1 -(3-methyl-benzyl)-1 4,5,6,7,8-hexahydro- 3-(4-Chloro-phenyl)-1 -(4-fluoro-benzyl)-1 4.5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 3-(4-Chioro-phenyl)-1 ~(3-fluoro-benzyl)-1 4.5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 3-(4-Chioro-phenyl)-1 -(4-methyl-benzyl)-1 ,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; triaza-azulene; 3-(4-Chloro-phenyl)-1 -(3-fluoro-4-methyl-benzyl)-1,4,5,6,7,8- ers 1,2,6-triaza-azulene; 5-[3-(4-Chloro-phenyl)-5,6,7 8-tetrahydro-4 1 ,2,6-triaza-azulen-1- arenes 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1- yl]-pentanoic acid; yl}-pentan-1-ol; yi]-butyric acid methyl ester; yl]-butyric acid;
4-[3-(4-Chloro-phe nyl)-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1- yl]-butan-1-ol; 3-(4-Chloro-phenyl)-1 -(3-fluoro-4-methoxy-benzyl)-1 ,4,5,6,7,8-
El Birnie 3-(4-Chloro-phenyl)-1 -(4-nitro-benzyl)-1 4.5,6,7,8-hexahydro-1,2,6-
El ie 4-(3-Phenyl-5,6,7 8-tetrahydro-4 H-1 2 6-triaza-azulen-1-ylmethyl)-
I =
N-[4-(3-Phenyl-5,6,7 8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1- yimethyl)-phenyl}-methanesulfonamide;
N,N-[4-(3-phenyl-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1- yimethyl)-phenyl]-dimethanesulfonamide; 1,2,6-triaza-azulene; azulene; 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; azulene;
1-(2-Bromo-benzyl)-3-(4-chioro-phenyl)-1,4.,5.6,7,8-hexahydro- 1,2,6-triaza-azulene; 113 , ‘ no 1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-1-(2-ethyl-butyl)-1 ,4.5,6,7,8-hexahydro-1,2,6- triaza-azulene; 3-(4-Chloro-phenyl)-1 -(5-chloro-thiophen-2-yimethyl)-1,4,5,6,7,8- 1,2,6-triaza-azulene; ; 1,2,6-triaza-azulene; azulene; hexahydro-1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-1-(tetrahydro-pyran-4-ylmethyl)-1,4,5,6,7,8- rr 1,2,6-triaza-azulene; 1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-1-(3-methyl-butyl)-1,4,5,6,7,8-hexahydro-1,2,6- [Ee hexahydro-1,2,6-triaza-azulene hexahydro-1,2,6-triaza-azulene, triaza-azulene; hexahydro-1,2,6-triaza-azulene;
3-(4-Chloro-phenyli)-1 -(2,4,6-trifluoro-benzyl)-1 ,4,5,6,7,8- 2.[3-(4-Chloro-phenyl)-5,8,7,8-tetrahydro-4H-1 ,2,6-triaza-azulen-1- 3-(4-Chloro-phenyl)-1 -naphthalen-2-ylmethyl-1,4,5,6,7,8- 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1 ,2,6-triaza-azulen-1- yimethyl}-furan-2-carboxylic acid ethyl ester; 3-(4-Chloro-phenyl)-1-naphthalen-1-ylmethyl-1 ,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; [3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1 ,2,6-triaza-azulen-1-ylj- acetic acid methyl ester; 2-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1-
I nie 3-(4-Chloro-phenyl)-1-(3,4,5-trimethoxy-benzyl)-1 ,4,5,6,7,8- re 3-(4-Chloro-phenyl)-1-(2,6-dimethyl-benzyl)-1 ,4,5,6,7,8-hexahydro- en 1-(3,4-Bis-benzyloxy-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8- soe yimethyl]-phenol; yimethyl]-phenol; yimethyl]-3-methyl-phenol; ylmethyl]-benzene-1,2-diol; yimethyl]-2-fluoro-phenol; yimethyl]-phenol;
Claims (1)
- What is claimed is:1. A compound having serotonin receptor modulating activity of formula (1), (11), or (I): R? CYC-(ALK), J CYCHALKI—N A CY CHALK) NA '¢ ) Ar SE " kr " Wi " |N (1) (1) (1m) wherein mis 0, 10r2; nis1,2or3; pis 1, 2 or 3, with the proviso that where mis 1, p is not 1; m+n is less than or equal to 4; m+p is less than or equal to 4, : qisOori; ris0, 1,2, 3, 4, or 5; R3 is -C,alkyl, allyl, propargyl, or benzyl, each optionally substituted with-C1.3alkyl, —OH, or halo; Ar is an aryl or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R' or di-substituted on adjacent carbons with -OC;4alkyleneO-, -(CH2)2.aNH-, -(CH2)1.2NH(CHa)-, -(CH2)23N(C14alkyl)- or -(CHz)1.2N(C14alkyl)(CH2)-; R' is selected from the group consisting of -OH, -Cssalkyl, -OC;.galkyl, -Cosalkenyl, -OCa.galkenyl, -Casalkynyl, -OCssealkynyl, -CN, -NO,, -N(R*)R? (wherein R’ and R* are independently selected from H or Cy.galkyl), -(C=O)N(R¥)R?, -(N-R)COR!, -(N-R")SOC;.salkyl (wherein R'is H or C1ealkyl), -(C=0)C;.ealkyl, -(S=(O)n)-C1-6alkyl (wherein n is selected from0, 1 or 2), -SO.N(R")R? -SCF;, halo, -CF, -OCF3, -COOH and © -COOC, alkyl; b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(Csalkyl) and which moiety has up to one additional : carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R"; c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R'; d) naphthyl, optionally mono-, di- or tri-substituted with R"; . e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one "carbon atom replaced by >0, >S, >NH or >N(C,alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R and i} &@ monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R" g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, : where the resultant substituted moiety is optionally further mono-, di-substituent independently selected from the group consisting of: -OH,-OC.calkyl, -OCa.scycloalkyl, -CN, -NOa, -N(R*)R" (wherein R® and R are independently selected from H, C1.ealkyl or Czealkenyl), -(C=O)N(R®*)R®, -(N-R%)COR?®, -(N-R°)SO.C1.salkyl (wherein R® is H or Cy.¢alkyl), -(C=0)C1.¢alkyl, -(S=(0)q)-C1.salkyl (wherein d is selected from 0, 1 or 2),-SO.N(R%)R®, -SCF3, halo, -CF3, -OCF3, -COOH and -COOC;.galkyl; CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R? or di-substituted on adjacent carbons with -OC,.4alkyleneO-, -(CHz)2.sNH-, -(CHz)1.2NH(CHz)-, -(CHz)2.aN(C14alkyl)- or -(CHg)1.2N(C1-4alkyl)(CHg)-; RY is selected from the group consisting of —OH, -C1.galkyl, -0C, alkyl, -Csecycloalkyl, -OCsgcycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C,.¢alkyl or Co¢alkenyl, or R® and R may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C,.qalkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R*)R®, -(N-R°)COR®, -(N-R®)SO,C1.¢alkyl (wherein R® is H or Cy.galkyl or two RC in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO2C1.salkyl)z, -(C=0)C,.salkyl, -(S=(0)q)-C1-6alkyl (wherein d is selected from 0, 1 or 2), -SO.N(R*)R®, -SCF3, halo, -CF3, -OCFs, -COOH and -COOC, alkyl; ii} phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0, >S, >NH or >N(C;.salkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY,iii) pheny! fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring,which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R%:iv) naphthyl, optionally mono-, di- or tri-substituted with RY;v) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C,.4alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R%,;vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with RY,vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R% and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents R%; R' is selected from the group consisting of H, C+.7alkyl, C2.7alkenyl, Co7alkynyl,Ca.scycloalkyl, CascycloalkylC,.7alkyl, Cs.,cycloalkenyl,Cs.7cycloalkenylC.7alkyl and benzo-fusedCa scycloalkyl, each optionally mono-, di-, or tri-substituted with RP; RP is selected from the group consisting of —-OH, -OC;salkyl,-Ca.scycloalkyl, -OCsecycloalkyl, -CN, -NO,, phenyl, pyridyl, thieny!l, : furanyl, pyrrolyl, -N(R®)R" (wherein R® and R" are independently selected from H or Cy.salkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C,.4alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R®)R", -(N-R")COR", -(N-R")SO.C;.salkyl (wherein R" is H or C.¢alkyl or two R" in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)Cjgalkyl, -(S=(0)n)-C1ealkyl (wherein n is selected from 0, 1 or 2), -SO2N(R®*)R", -SCF3, halo, -CF3, -OCF3, -COOH and -COOC;.galkyl,- wherein the foregoing phenyl, pyridyl, thienyl, furany! and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C1.¢alkyl, -OC1.¢alkyl, -CN, -NO,, -N(R*)R® (wherein R? and R® are independently selected from H, C,.salkyl or C-salkenyl), -(C=0)N(R?)R", -(N-R°)COR?®, -(N-R°)SO.C.galkyl (wherein R® is H or Cy_galkyl), -(C=0)C1.galkyl, -(S=(0)q)-C1-alkyl (wherein d is selected from 0, 1 or 2), -SON(R*R®, -SCF3, halo, -CF3, -OCF3, -COOH and -COOC alkyl;R? is selected from the group consisting of H, Ci.7alkyl, Ca7alkenyl, C.7alkynyl and Ca.rcycloalkyi; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.2. The compound of claim 1 wherein mis 1 or 2.3. The compound of claim 1 wherein mis 1.4. The compound of claim 1 wherein nis 1 or 2.5. The compound of claim 1 wherein pis 1 or 2.6. The compound of claim 1 wherein m+n is 2 or 3.7. The compound of claim 1 wherein m+p is 2 or 3.8. The compound of claim 1 wherein q is 1.9. The compound of claim 1 whereinris 0, 1, or 2.10. The compound of claim 1 wherein r is 4.11. The compound of claim 1 wherein R®, optionally substituted, is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, allyl, propargyl, and benzyl.12. The compound of claim 1 wherein R® is methyl.13. The compound of claim 1 wherein Ar, optionally substituted, is selected from the group consisting of:a) phenyl, 5-, 6-, 7-, 8-benzo-1,4-dioxanyl, 4-, 5-, 6-, 7-benzo-1,3- dioxolyl, 4-, 5-, 6-, 7-indolinyl, 4-, 5-, 6-, 7-isoindolinyl, 1,2,3,4-tetrahydro- quinolin-4, 5, 6 or 7-yl, 1,2,3,4-tetrahydro-isoquinolin-4, 5, 6 or 7-yl, b) 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1,2-a)pyridin-5, 6, 7 or 8- yl, pyrazolo[1,5-a)pyridin-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, c) 5-, 6-, 7- or 8-isoquinolinyl, 5-, 6-, 7- or 8-quinolinyl, 5-, 6-, 7- or 8- quinoxalinyl, 5-, 6-, 7- or 8-quinazolinyl, d) naphthyl, e) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, © 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2- benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indolyl, 2- benzthiazolyl, 2-benzimidazolyl, 3-indazolyl, f) pyridinyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, 1-, 3- or 4-isoquinolinyl, 2-, 3- or 4-quinolinyl, 2- or 3-quinoxalinyl, 2- or 4-quinazolinyl, [1,5], [1,6], [1,7], or [1,8]naphthyridin-2-, 3-, or 4-yl, [2,5], [2,6], [2,7], [2,8]naphthyridin-1-, 3-, or 4-yl, and g) biphenyl, 4-tetrazolylphenyl.14. The compound of claim 1 wherein Ar, optionally substituted, is selected from the group consisting of phenyl, pyridyl, thiophen-2-yl and thiophen-3-yl.15. The compound of claim 1 wherein Ar is selected from the group consisting of phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methyiphenyl, 4-ethyiphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyi, 4-trifluoromethyiphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 3-cyanophenyl,4-cyanophenyl, 3-acetylphenyl, 4-acetylphenyl, 3,4-diflucrophenyi, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-chloro-4-fluorophenyl, 3-fluoro-4-chlorophenyl, benzo[1,3]dioxol-4 or 5-yl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-hydroxy-2-methylphenyl, 4-hydroxy-3-fluorophenyl, 3,4- dihydroxyphenyl,4-dimethylaminophenyl!, 4-carbamoylphenyl, 4-fluoro-3- methylphenyl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, 5- chlorothiophen-2-yl, 5-methyithiophen-2-yl, 5-chiorothiophen-3-yi, 5- methyithiophen-3-yl, 4'-chlorobiphenyl, and 4-tetrazolylphenyl.16. The compound of claim 1 wherein ALK, optionally substituted, is selected from the group consisting of methylene, ethylene, propylene, butylene, tert-butylene, pentylene, 1-ethylpropylene, 2-ethylpropylene, 2- ; ethylbutylene, isopropylene, but-3-enylene, isobutylene, 3-methylbutylene, allylene, and prop-2-ynylene.17. The compound of claim 1 wherein ALK is selected from the group consisting of methylene, trifluoromethylmethylene, methoxycarbonyimethyl, methylcarbamoylmethyl, ethylene, propylene, 3-methoxycarbony! propylene, 3- carboxy propylene, butylene, tert-butylene, 4-hydroxybutylene, 4- methoxycarbonyl butylene, 4-carboxy butylene, pentylene, 5-hydroxypentylene, 1-ethylpropylene, 2-ethylpropylene, 2-ethylbutylene, isopropylene, but-3- enylene, isobutylene, 3-methylbutylene, prop-2-ynylene, 2- dimethylaminoethylene, and 2-cyanoethylene.18. The compound of claim 1 wherein CYC, optionally substituted, is hydrogen or is selected from the group consisting of: i) phenyl, 5-, 6-, 7-, 8-benzo-1,4-dioxanyl, 4-, 5-, 6-, 7-benzo-1,3-dioxolyl, 4-, 5-, 6-, 7-indolinyl, 4-, 5-, 6-, 7-isoindolinyl, 1,2,3,4-tetrahydro-quinolin-4, 5, 6 or 7-yl 1,2,3,4-tetrahydro-isoquinolin-4, 5, 6 or 7-yl, ii) 4-, 5-, 6- or 7-benzoxazolyl, 4-, 5-, 6- or 7-benzothiophenyl, 4-, 5-, 6- or 7-benzofuranyl, 4-, 5-, 6- or 7-indolyl, 4-, 5-, 6- or 7-benzthiazolyl, 4-, 5-, 6- or 7-benzimidazolyl, 4-, 5-, 6- or 7-indazolyl, imidazo[1,2-a]pyridin-5, 6, 7 or 8-yl, pyrazolo[1,5-a}pyridin-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-blpyridin-5, 6 or 7-yl, iii) 5-, 6-, 7- or 8-isoquinolinyl, 5-, 6-, 7- or 8-quinolinyl, 5-, 6-, 7- or 8- quinoxalinyl, 5-, 6-, 7- or 8-quinazolinyl, iv) naphthyl, v) furanyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazoly|, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 3-indoxazinyl, 2- benzoxazolyl, 2- or 3-benzothiophenyl, 2- or 3-benzofuranyl, 2- or 3-indolyl, 2- benzthiazolyl, 2-benzimidazolyl, 3-indazolyl, vi) pyridinyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, 1-, 3- or 4-isoquinolinyl, 2-, 3- or 4-quinolinyl, 2- or 3-quinoxalinyl, 2- or 4-quinazolinyl, [1,5], [1,6], [1,7], or [1,8]naphthyridin-2-, 3-, or 4-yl, [2,5], [2,6], [2,7], [2,8]naphthyridin-1-, 3-, or 4-yl, vii) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, adamantyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, piperidinyl, homopiperidinyl, azepanyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinonyl, indanyl, dihydroindolyi, oxindolyl, dihydropyrrolopyridinyl, and viii) bicyclo[4.1.0]heptane, octahydroindolyl, octahydroisoindolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydropyrrolopyridinyl, and octahydropyrrolopyrrolidinyl.19. The compound of claim 1 wherein CYC, optionally substituted, is selected from the group consisting of hydrogen, phenyl, indolyl, benzthiazolyl, isoquinolyl, quinazolinyl, naphthalen-1 or 2-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl, furan-3-yl, pyridinyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, piperidin-2,3 or 4-yl, 2-pyrrolin-2, 3, 4 or 5-yl, 3-pyrrolin-2 or 3-yl, 2- pyrazolin-3, 4 or 5-yl, morpholin-2, 3, 5 or 6-yl, thiomorpholin-2, 3, 5 or 6-yl, piperazin-2, 3, 5 or 6-yl, pyrrolidin-2 or 3-yl, homopiperidinyl, adamantanyl, and octahydroindolyl.20. The compound of claim 1 wherein CYC, optionally substituted, is selected from the group consisting of hydrogen, phenyl, pyridyl, cyclobutyl, cyclopentyl, cyclohexyl, thiophen-2-yl, thiophen-3-yl, tetrahydropyranyl, furan-2- yl, furan-3-yl and naphthalen-1or 2-yl. -21. The compound of claim 1 wherein CYC is selected from the group consisting of hydrogen, phenyl, 2-methoxyphenyi, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-ethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-bromopheny!, 3-bromophenyl, 4-bromophenyt, 2-trifluoromethylphenyi, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-trittuoromethoxyphenyi, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-acetylphenyl, 4-acetylphenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 2,3-difluorophenyl, 2,3-dichlorophenyl, 16 2,4-difluorophenyl, 2,4-dichiorophenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2,6-dimethylphenyl, 2,4,6-trifluorophenyl, 2,4,6-trichiorophenyl, 3,4,5-trimethoxyphenyl, cyclobutyl, cyclohexyl, cyclopentyl, 4-fluoro-3- methylphenyl, 3-nitrophenyl, 4-nitrophenyl, 4-methyl-3-fluorophenyl, 3,4- dimethylphenyl, 4-methoxy-3-fluorophenyl, 4-methoxy-2-methylphenyl, 3-aminophenyl, 4-aminophenyl, 4-carbomethoxyphenyl, 3-methanesulfonylamino-phenyl, 4-methanesulfonylamino-phenyl, 3-dimethanesulfonylamino-phenyl, 4-dimethanesulfonylamino-phenyl, thiophen-2-yl, thiophen-3-yl, 5-chiorothiophen-2-yl, benzo[1,3]dioxol-4 or 5-yl, tetrahydropyran-2,3 or 4-yl, furan-2-yl, furan-3-yl, 5-carboxyethyl-furan-2-yl, naphthalen-1 or 2-yl, 3,4-bisbenzyloxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 4-hydroxy-2-methylphenyl, 4-hydroxy-3- fluorophenyl and 3,4-dihydroxyphenyl.22. The compounds of claim 1 wherein R' is selected from the group consisting of hydrogen, Cy.aalkyl, Co4alkenyl, Ca.salkynyl, Csecycloalkyl, Ca. scycloalkylC,.aalkyl, Csecycloalkenyl, benzo-fusedCs.ecycloalkyl, each optionally mono-, di-, or tri-substituted with RP.23. The compound of claim 1 wherein R', optionally RP substituted, is selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.24. The compound of claim 1 wherein R'is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 3-hydroxypropy!, benzyl, 3,4-dimethoxybenzyl, methoxycarbonylmethyl, carbamoyimethyl, phenethyl, phenpropyl, and hydroxyethyl.25. The compound of claim 1 wherein R? is hydrogen, Ci.salkyl, Co4alkenyl, Caalkynyl, or Caecycloalkyl.26. The compound of claim 1 wherein R? is hydrogen or methyl.27. The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 1 1-Benzyl-3-(4-nitro-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- cJpyridine; 2 1-Benzyl-3-(3-chloro-4-fluoro-phenyl)-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-c]pyridine; 3 4-(1-Benzyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-c]pyridin-3-yl)-phenol; 4 1-Benzyl-3-(4-trifluoromethoxy-phenyl)-4,5,6,7-tetrahydro-1 H pyrrolo[3,2-c]pyridine; 5 1-Benzyl-3-(5-chloro-thiophen-2-yl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 6 1-Benzyl-3-thiophen-2-yl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-clpyridine; 7 1-(3-Chloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; 8 1-Benzyl-3-(3-fluoro-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- Clpyridine; 9 3-(4-Chloro-phenyl)-1-(2-fluoro-benzyl)-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-c]pyridine;1-(3-Chloro-benzyl)-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-1H- pyrrolo[3,2-c]pyridine; 11 1-(2-Chloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 12 1-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-c]pyridine; 13 1-Benzyl-3-(2,4-dichloro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; 14 1-(4-Methoxy-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 1-(2-Chloro-benzyl)-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-c]pyridine; 16 1-(2,4-Dichloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; 17 1-Benzyl-2-methyl-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 18 1-Benzyl-3-p-tolyl-4,5,6,7-tetrahydro-1 H-pyrrolo{3,2-c]pyridine; 19 1-Benzyl-3-(3,4-dichloro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- Clpyridine; 3-Benzo[1,3]dioxol-5-yl-1-benzyl-4,5,6,7-tetrahydro-1 Hpyrrolo[3,2- clpyridine; 21 1-Benzyl-3-(4-fluoro-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; 22 1-Butyl-3-p-tolyl-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2-c]pyridine; 23 1-Benzyl-3-(4-bromo-phenyl)-4,5,6,7-tetrahydro-1 H-pyrrolo[3,2- clpyridine; . 24 1-Benzyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-1H- pyrrolo[3,2-c]pyridine; 1-Benzyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- cJpyridine; 26 1-Benzyl-3-phenyl-1,4,5,6,7,8-hexahydro-pyrrolo[2,3-dlazepine;27 1-Benzyl-3-(5-methyl-thiophen-2-yl)-4,5 6,7-tetrahydro-1H-pyrrolo[3,2- cJpyridine; 28 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-pyrrolo[2,3- dlazepine; 29 1-Benzyl-3-(5-chloro-thiophen-2-yl)-1,4,5,6,7,8-hexahydro-pyrrolo[2,3- dlazepine; 1-(4-Chloro-benzyl)-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 31 1-Benzyl-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine; 32 1-Benzyl-3-(3-chloro-phenyl)-1,4,5,6,7,8-hexahydro-pyrrolo[2,3- dlazepine; 33 1-Benzyl-3-(3-chloro-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine; 34 1-Benzyl-3-(4-methoxy-phenyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- Clpyridine; 1-Benzyl-3-(4-chloro-phenyl)-5-ethyl-4,5,6,7-tetrahydro-1H- pyrrolo[3,2-c]pyridine; 36 1-Benzyl-3-(4-chloro-phenyl)-5-isopropyi-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-c]pyridine; 37 3-[1-Benzyl-3-(4-chioro-phenyl)-1,4,6,7-tetrahydro-pyrrolo[3,2- cJpyridin-5-yl]-propan-1-ol; 38 1-Benzyl-3-(4-chloro-phenyl)-5-methyl-4,5,6,7-tetrahydro-1 +H pyrrolo[3,2-c]pyridine; 39 1-Benzyl-3-(3-chloro-phenyl)-5-methyl-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-clpyridine; 40 1-Benzyl-3-(3-chloro-4-fluoro-phenyl)-5-methyl-4,5,6,7-tetrahydro-1 H- pyrrolo[3,2-clpyridine; 41 1,5-Dibenzyl-3-phenyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-clpyridine; and 42 1-Benzyl-5-isopropyl-3-phenyi-4,5,6,7-tetrahydro-1H-pyrrolo[3,2- clpyridine.28. The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 1-Benzyl-3-(4-trifluoromethyl-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6- 43 triaza-azulene; 44 1-Benzyl-3-phenyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 45 1-Benzyl-3-(2-fluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 46 1-Benzyl-3-(3-fluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulens; 47 1-Benzyl-3-(4-fluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- : azulene; 48 1-Benzyl-3-(2,3-difluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 49 1-Benzyl-3-(3,4-dichloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 50 1-]4-(1-Benzyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- phenyl]-ethanone; 51 1-Benzyl-3-(4-trifluoromethoxy-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; - 1-Benzyl-3-(3-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 53 3-(1-Benzyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; ” 4-(1-Benzyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 55 1-(4-Chioro-benzyl)-3-phenyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 56 1-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 57 1-Benzyl-3-phenyl-6-propyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene, 5g 1-Benzyl-6-isopropyl-3-phenyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene;1-Benzyl-3-(4-chloro-phenyi)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- > azulene; 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,5-triaza- °0 azulene; 3-(4-Chloro-phenyl)-1-methyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- ® azulene; 3-(4-Chloro-phenyl)-1-ethyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- 83 azulene; 65 3-(4-Chloro-phenyl)-1-propyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; &7 1-Butyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 69 3-(4-Chloro-phenyl)-1-(2-cyciohexyl-ethyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 74 3-(4-Chloro-phenyl)-1-phenethyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 73 3-(4-Chiloro-phenyl)-1-(4-fluoro-3-methyl-benzyl)-1,4,5,6,7,8- : hexahydro-1,2,6-triaza-azulene; 74 3-(4-Chloro-phenyl)-1-(3-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 75 3-(4-Chloro-phenyl)-1-(4-fluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 76 3-(4-Chloro-phenyl)-1-(3-fluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 77 3-(4-Chloro-phenyl)-1-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 78 3-(4-Chloro-phenyl)-1-(3,4-difluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 79 3-(4-Chloro-phenyl)-1-(3-nitro-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 80 3-(4-Chloro-phenyl)-1-(3-fluoro-4-methyl-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene;3-(4-Chloro-phenyl)-1-(3,4-dimethyl-benzyl)-1,4,5,6,7,8-hexahydro- 81 1,2,6-triaza-azulene; 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- 85 yl]-pentanoic acid methyl ester; 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H1,2,6-triaza-azulen-1- 86 yl]-pentanoic acid; 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- 87 yl]-pentan-1-ol; 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- 58 yl)-butyric acid methyl ester; o1 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- yl]-butyric acid; 93 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yl}-butan-1-ol; 56 3-(4-Chloro-phenyl)-1-(3-fluoro-4-methoxy-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; o8 3-(4-Chloro-phenyl)-1-(4-nitro-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 4-(3-Phenyl-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-1-yimethyl)- 9 phenylamine; 100 N-[4-(3-Phenyl-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yimethyl)-phenyl]-methanesulfonamide; 101 N,N-{4-(3-phenyl-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- yimethyl)-phenyl}-dimethanesulfonamide; 102 1-Benzyl-3-p-tolyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 103 3-(4-Chloro-phenyl)-1-thiophen-2-yimethyl-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 104 1-Benzyl-3-thiophen-2-yl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 105 3-(4-Chioro-phenyl)-1-(3-methoxy-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 106 3-(4-Chloro-phenyl)-1-(2-fluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene;3-(4-Chloro-phenyl)-1-(2-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 107 1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-1-(2,4-difiuoro-benzyl)-1,4,5,6,7,8-hexahydro- 108 1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-1-(2-methoxy-benzyl)-1,4,5,6,7,8-hexahydro- 109 1 2,6-triaza-azulene; 1-(2-Chloro-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro- 110 1,2,6-triaza-azulene; 1-But-3-enyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- ha azulenes; 112 1-(2-Bromo-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 113 1-(4-Bromo-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 114 3-(4-Chloro-phenyl)-1-(2-ethyl-butyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 115 3-(4-Chloro-phenyl)-1-(5-chloro-thiophen-2-yimethyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 116 1-(3-Bromo-benzyl)-3-(4-chioro-phenyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; ; 17 3-(4-Chloro-phenyl)-1-cyclohexylmethyl-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 118 3-(4-Chloro-phenyt)-1-isobutyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 119 1-Benzo[1,3]dioxol-5-yimethyl-3-(4-chloro-phenyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 120 3-(4-Chloro-phenyl)-1-(tetrahydro-pyran-4-ylmethy!)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 121 '3-(4-Chloro-phenyl)-1-(2,6-difluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 123 3-(4-Chloro-phenyl)-1-(4-methoxy-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene;3-(4-Chloro-phenyl)-1-(3-methyl-butyl)-1,4,5,6,7,8-hexahydro-1,2,6- 124 triaza-azulene; 3-(4-Chloro-phenyt)-1-(2-trifluoromethyl-benzyl)-1,4,5,6,7,8- 125 hexahydro-1,2,6-triaza-azulene 3-(4-Chloro-phenyl)-1-(4-methoxy-2-methyl-benzyl)-1,4,5,6,7,8- 128 hexahydro-1,2,6-triaza-azulene; 134 3-(4-Chloro-phenyl)-1 -prop-2-ynyl-1 ,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 3-(4-Chloro-phenyl)-1-pentafluorophenyimethyl-1,4,5,6,7,8- 195 hexahydro-1,2,6-triaza-azulene; 137 3-(4-Chloro-phenyl)-1-(2,4,6-trifluoro-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 138 2-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yimethyl}-benzonitrile; 142 3-(4-Chloro-phenyl)-1-naphthalen-2-ylmethyl-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; a4 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yimethyl]-furan-2-carboxylic acid ethyl ester; . 145 3-(4-Chioro-phenyl)-1-naphthalen-1-yimethyl-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 147 [3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1-yl}- acetic acid methyl ester; 148 2-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yl]-N-methyl-acetamide; 150 3-(4-Chloro-phenyl)-1-(3,4,5-trimethoxy-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 152 3-(4-Chloro-phenyl)-1-(2,6-dimethyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 154 1-(3,4-Bis-benzyloxy-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 156 3-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- ylimethyl]-phenol;4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- 157 ylimethyl}-phenol; 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- 158 yimethyl]-3-methyl-phenol; 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- 159 yimethyl]-benzene-1,2-diol; 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H1,2,6-triaza-azulen-1- 160 ylmethyl]-2-fluoro-phenol; 2-[3-(4-Chioro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- 162 ylmethyl}-phenol; 165 1-Benzyl-3-(4-chloro-phenyl)-6-methyl-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 166 1-Benzyl-3-(4-chloro-phenyl)-6-ethyl-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 167 3-(4-Chloro-phenyl)-6-(3,4-dimethoxy-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 168 1-Butyl-3-(4-chloro-phenyl)-6-(3,4-dimethoxy-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 169 1-Benzyl-3-(4-chloro-phenyl)-6-(3,4-dimethoxy-benzyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 170 [1-Benzyl-3-(4-chloro-phenyl)-4,5,7,8-tetrahydro-1H-1,2,6-triaza- azulen-6-yl)-acetic acid methyl ester; 171 2-[1-Benzyl-3-(4-chloro-phenyl)-4,5,7,8-tetrahydro-1H+1,2,6-triaza- azulen-6-yl]-ethanol; 172 3-(4-Chloro-phenyl)-1-phenyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 173 3-(4-Chloro-phenyl)-1-(2-methyl-benzyl)-4,5,6,7,8,9-hexahydro-1 H- 1,2,6-triaza-cyclopentacyclooctene; 174 3-(4-Chloro-phenyl)-1-(2-methyl-benzyl)-4,5,6,7,8,9-hexahydro-1 H- 1,2,7-triaza-cyclopentacyclooctene; 475 3-(4-Chloro-phenyl)-1-(2-methyl-benzyl)-4,5,6,7-tetrahydro-1 H- pyrazolo[3,4-c]pyridine;{4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- 280 ylmethyl]-phenyl}-methyl-amine; 3-(4-Chloro-phenyl)-1-cyclobutyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- 237 azulene; 3-(4-Chloro-phenyl)-1-cyclohexyi-1,4,5,6,7,8-hexahydro-1,2,6- 239 triaza-azulene; 0854 3-(4-Chloro-phenyl)-1-cycloheptyl-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 256 3-(4-Chloro-phenyl)-1-cyclooctyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; ova 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene citrate salt; 316 3-(4-Chloro-phenyl)-1-pyridin-4-ylmethyl-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 317 3-(4-Chloro-phenyl)-1-pyridin-2-ylmethyl-1,4,5,6,7,8-hexahydro- : 1,2,6-triaza-azulene; 319 3-(4-Chloro-phenyl)-1-pyridin-3-ylmethyl-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 320 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- ylmethyl]-benzoic acid methyl ester; 391 3-(4-Chloro-phenyl)-1-(tetrahydro-pyran-4-yl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 322 3-(4-Chloro-phenyl)-1-(4-methyl-cyclohexyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 323 {2-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- yl]-ethyl}-dimethyl-amine. 304 3-(4-Chloro-phenyl)-1-(1-oxy-pyridin-2-yimethyl)-1,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 305 2-[1-Benzyl-3-(4-chloro-phenyl)-4,5,7,8-tetrahydro-1H-1,2,6-triaza- azulen-6-yl]-acetamide; 326 3-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-1- yl}-propionitrile.a3 1-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro- 1,2,5-triaza-azulene; 308 3-(4-Chloro-phenyl)-1-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,5-triaza-azulene; 334 3-(4-Chloro-phenyl)-1-(3,4-difluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,5-triaza-azulene; oy 3-(4-Chloro-phenyl)-1-(3-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,5-triaza-azulene; 208 3-(4-Chloro-phenyl)-1-(3-fluoro-4-methyl-benzyl)-1,4,5,6,7,8- hexahydro-1,2,5-triaza-azulene; and 237 3-(4-Chloro-phenyl)-1-(4-fluoro-3-methyi-benzyl)-1,4,5,6,7,8- ~ hexahydro-1,2,5-triaza-azulene.29. The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 62 3-(4-Chloro-phenyl)-2-methyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 64 3-(4-Chloro-phenyl)-2-ethyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 66 3-(4-Chloro-phenyl)-2-propyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 68 2-Butyl-3-(4-chloro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 3-(4-Chloro-phenyl)-2-(2-cyclohexyl-ethyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 70 3-(4-Chloro-phenyl)-2-phenethyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 82 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-2- yll-pentanoic acid methyl ester; 83 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-2- yl]-pentanoic acid; 84 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4/+1,2,6-triaza-azulen-2- yll-pentan-1-ol;4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4+1,2,6-triaza-azulen-2- 89 yl}-butyric acid methyl ester; 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-2- 90 yl]-butyric acid; 4-[3-(4-Chloro-phenyl)-5,6,7 ,8-tetrahydro-4 H-1,2,6-triaza-azulen-2- 92 yl}-butan-1-ol; 3-(4-Chloro-phenyl)-2-(3,4-difluoro-benzyl)-2,4,5,6,7,8-hexahydro- 94 1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-2-(4-methyl-benzyl)-2,4,5,6,7,8-hexahydro- 9% 1,2,6-triaza-azulene; 97 3-(4-Chloro-phenyl)-2-(3-fluoro-4-methoxy-benzyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 122 3-(4-Chloro-phenyl)-2-cyclohexylmethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene, 126 3-(4-Chloro-phenyl)-2-(2-methyl-benzyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 127 2-Benzyl-3-(4-chloro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 129 3-(4-Chloro-phenyl)-2-(2,4-difluoro-benzyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 130 5-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-2- ylmethyl]-furan-2-carboxylic acid ethyl ester; 131 3-(4-Chloro-phenyl)-2-isobutyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 130 3-(4-Chloro-phenyl)-2-(2-methoxy-benzyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 133 2-Benzyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 136 3-(4-Chloro-phenyl)-2-thiophen-2-ylmethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 139 3-(4-Chloro-phenyl)-2-(5-chloro-thiophen-2-ylmethyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 140 3-(4-Chloro-phenyl)-2-(2,6-difluoro-benzyl)-2,4,5,6,7,8-hexahydro- : 1,2,6-triaza-azulene; :3-(4-Chloro-phenyl)-2-(2-trifluoromethyi-benzyl)-2,4,5,6,7,8- 141 hexahydro-1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-2-(2-ethyl-butyl)-2,4,5,6,7,8-hexahydro-1,2,6- 143 triaza-azulene; 2-Benzo[1,3]dioxol-5-yimethyl-3-(4-chloro-phenyl)-2,4,5,6,7,8- 146 hexahydro-1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-2-pentafluorophenyimethyl-2,4,5,6,7,8- 149 hexahydro-1,2,6-triaza-azulene; 151 3-(4-Chloro-phenyl)-2-naphthalen-1-ylmethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 153 3-(4-Chloro-phenyl)-2-(3,4,5-trimethoxy-benzyl)-2,4,5,6,7,8- } hexahydro-1,2,6-triaza-azulene; 155 2-(3,4-Bis-benzyloxy-benzyl)-3-(4-chioro-phenyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 161 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-2- ylmethyl]-2-fluoro-phenol; 163 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1 ,2,6-triaza-azulen-2- ylmethyl]-3-methyi-phenol; 164 2-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-2- yimethyl]-phenol; 176 2,3-Diphenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 177 2-Cyclohexyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 178 3-(4-Chloro-phenyl)-2-cyclohexyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 179 2-Cyclohexyl-3-(4-trifluoromethyl-phenyi)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 180 2-Cyclopentyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 181 3-(4-Chloro-phenyl)-2-cyclopentyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 182 2-Cyclopentyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 183 2-(1-Ethyl-propyl)-3-(3-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene;2-(1-Ethyl-propyl)-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 184 triaza-azulene; 2-(1-Ethyl-propyl)-3-thiophen-3-yl-2,4,5,6,7,8-hexahydro-1,2,6- 185 triaza-azulene, 2-(1-Ethyl-propyl)-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 186 azulene; 3-(4-Chloro-phenyl)-2-(2,2,2-trifluoro-ethyl)-2,4,5,6,7,8-hexahydro- 187 1,2,6-triaza-azulene; 188 2-(2,2,2-Trifluoro-ethyl)-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 189 2-Isopropyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 190 3-(4-Fluoro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 191 2-(1 -Ethyl-propyl)-3-thiophen-2-y}-2,4,5,6,7,8-hexahydro-1 ,2,6- triaza-azulene; 192 2-Cyclopentyl-3-thiophen-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 193 2-Ethyl-3-phenyi-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 194 2-Ethyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 196 2-Ethyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 196 2-(3-Chloro-phenyl)-3-phenyl-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 197 2+(3-Fluoro-phenyl)-3-phenyl-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 198 2-(2-Chloro-phenyl)-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 199 2-Phenyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 200 3-(4-Fluoro-phenyl)-2-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 201 3-(4-Chloro-phenyl)-2-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene;3-(3-Chloro-phenyl)-2-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 202 azulene; 203 2-Phenyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 204 2,3-Diphenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine; 3-Phenyl-2-(3-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 205 triaza-azulene; 3-(4-Methoxy-phenyl)-2-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 208 azulene; 507 2-(4-Chloro-phenyl)-3-pheny-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 208 6-Methyl-2,3-diphenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 209 2-lsopropyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 290 3-(4-Ethyl-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 11 3-(4-Chloro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- . azulene; 212 4-(2-Isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 13 2-Isopropyi-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 214 2-Ethyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 215 2-tert-Butyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 016 2-tert-Butyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 217 2-Cyclopentyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 218 2-Cyclopentyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 219 3-(3-Chloro-phenyl)-2-cyclopentyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 220 2-Cyclopentyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 01 2-(3,3-Dimethyl-cyclopentyl)-3-pheny!-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene;2-(3,3-Dimethyl-cyclopentyl)-3-(4-fluoro-phenyi-2,4,5,6,7,8- 222 hexahydro-1,2,6-triaza-azulene; 3-(4-Chloro-phenyl)-2-(3,3-dimethyl-cyclopentyl)-2,4,5,6,7,8- 223 hexahydro-1,2,6-triaza-azulene; 004 2-Cyclohexyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; p05 2-Cyclohexyl-3-(3,4-difluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 226 2-Cyclohexyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 007 2-Cyclohexyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 228 4-(2-Cyclohexyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 009 3-(3-Chloro-phenyl)-2-cyclohexyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 031 3-(4-Fluoro-phenyl)-2-isopropyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3- c]pyridine; 032 2-Cyclopentyl-3-furan-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 033 2-Cyclopentyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 034 2-tert-Butyl-3-thiophen-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 235 2-tert-Butyl-3-furan-3-yi-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 236 2-Cyclopentyl-3-(3,4-difluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 038 3-(4-Chloro-phenyl)-2-cyclobutyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 240 2-tert-Butyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 041 3-(3-Chloro-4-fluoro-phenyl)-2-cyclopentyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene;” 2-Isopropyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 043 2-1sopropyl-3-(4-trifluoromethoxy-phenyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 044 2-1sopropyl-3-(4-isopropyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- . triaza-azulene; 045 3-(4-tert-Butyl-phenyl)-2-isopropyl-2,4,5,6,7 ,8-hexahydro-1,2,6- triaza-azulene; 246 2-Isopropyl-3-m-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 247 2-Isopropyl-3-o-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 048 3-(3,4-Dichloro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulens; 049 2-Benzyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 250 2-Isopropyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 051 3-(2-Chloro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 052 1-[4-(2-1sopropyl-2,4,5,6,7 ,8-hexahydro-1,2,6-triaza-azulen-3-yl)- phenyl]-ethanone; 053 2-Isopropyl-3-(4-nitro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 056 2-Benzyl-3-(4-chloro-phenyi)-2,4,5,6,7,8-hexahydro-1,2,5-triaza- azulene; ] 057 2-Ethyl-3-(4-ethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 058 4-(2-Ethyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 059 3-(4-Fluoro-phenyl)-2-isopropyl-6-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 260 3-(4-Fluoro-phenyl)-2,6-diisopropyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene;2-Ethyl-3-(4-isopropyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 261 azulene; 2-Ethyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 262 azulene; 2-Ethyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 263 triaza-azulene; 264 2-Ethyl-3-o-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 065 3-(2-Chloro-phenyl)-2-ethyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 266 2-Ethy}-3-(2-fluoro-pheny)-2,4.5,6,7,8-hexahydro-1 ,2,6-triaza- azulene; 067 3-(2,4-Dichloro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 268 [4-(2-Ethyl-2,4,5,6,7,8-hexahydro-1 2,6-triaza-azulen-3-yl)-phenyl]- dimethyl-amine; 269 6-Benzyl-3-(4-fluoro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 270 3-(4-Fluoro-phenyl)-2-isopropyl-6-(3-phenyi-propyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 071 3-(4-Fluoro-phenyl)-2-isopropyl-6-phenethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; and 270 3-(4-Fluoro-phenyl)-2-isopropyl-4,5,7,8-tetrahydro-2H-1,2,6-triaza- azulene-6-carboxylic acid tert-butyl ester. 074 3-(4'-Chloro-biphenyl-4-yl)-2-(2,2,2-trifluoro-ethyl)-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 278 3-(4'-Chloro-biphenyl-4-yl)-2-cyclopentyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 276 2-Cyclobutyt-3-phenyi-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 077 2-Cyclobutyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 278 2-Cyclobutyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 579 2-Cyclobutyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene;4-(2-Cyclobutyl-2,4,5,6,7, 8-hexahydro-1,2,6-triaza-azulen-3-yl)- 280 benzonitrile 281 2-Cyclopropyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 2-Cyclopropyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 262 triaza-azulene; 2-(1-Ethyl-propyl)-3-(4-fluoro-3-methyl-phenyl)-2,4,5,6,7,8- 283 hexahydro-1,2,6-triaza-azulene; 284 2-Cyclopropyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 285 2-Cyclopropyl-3-thiophen-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 286 4-(2-Cyclopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 087 6-Benzyl-2-isopropyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- clpyridine; 288 2-Isopropyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine; 289 6-Benzyl-2-isopropyl-3-thiophen-3-yl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine; 290 6-Benzyl-2-isopropy!-3-p-tolyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- clpyridine. 091 6-Benzyl-3-(4-fluoro-phenyl)-2-isopropyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine; ap 3-(4-Fluoro-phenytl)-2-isopropyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4- clpyridine; 293 2-lsopropyl-3-p-tolyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine; 094 2-Cyclopentyl-3-(4-fluoro-phenyl)-5,5,7,7-tetramethyl-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 005 2-Cyclopentyl-5,5,7,7-tetramethyl-3-phenyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 096 2-lsopropyl-5,5,7,7-tetramethyl-3-phenyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 097 3-(4-Fluoro-phenyl)-2-isopropyl-5,5,7,7-tetramethyl-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 298 2-sec-Butyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene;2-sec-Butyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- 299 azulene; 300 2-sec-Butyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 2-sec-Butyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 801 triaza-azulene; 2-Cyclopentyl-3-(4-fluoro-phenyl)-6-methyl-2,4,5,6,7,8-hexahydro- 302 1,2,6-triaza-azulene; 4-(2-lsopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- 803 benzamide; 304 2-Isopropyl-3-[4-(1H-tetrazol-5-yl)-phenyl]-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 305 6-Benzyl-3-(4-fluoro-phenyl)-2-isopropyl-8-methyl-2,4,5,6,7,8- hexahydro-1,2,6-triaza-azulene; 306 3-(4-Fluoro-phenyl)-2-isopropyl-8-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 307 3-(4-Fluoro-phenyl)-2-isopropyl-4-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 308 2-Cyclopentyi-3-(4-fluoro-phenyl)-7-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 309 2-Cyclopentyl-3-(4-fluoro-phenyl)-5-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 310 2-Cyclopentyl-7-methyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 311 2-Isopropyl-7-methyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 312 2-1sopropyl-5-methyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 313 3-(4-Fluoro-phenyl)-2-isopropyl-7-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 314 3-(4-Fluoro-phenyl)-2-isopropyl-5-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 315 2-lsopropyl-7-methyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene;3-(4-Chloro-phenyl)-2-pyridin-2-yimethyl-1,4,5,6,7,8-hexahydro- 318 1,2,6-triaza-azulene; 3-[3-(4-Chioro-phenyl)-5,6,7,8-tetrahydro-4H-1,2,6-triaza-azulen-2- 327 yl]-propionitrile; 3-(4-Chloro-phenyl)-2-cycloheptyl-2,4,5,6,7,8-hexahydro-1,2,6- 328 triaza-azulene; 3-(4-Chloro-phenyl)-2-cyclooctyl-2,4,5,6,7 ,8-hexahydro-1,2,6-triaza- 329 azulene; 3-(4-Chioro-phenyl)-2-(4-methyl-cyclohexyl)-2,4,5,6,7,8-hexahydro- 330 1,2,6-triaza-azulene; 2-Benzyl-3-(4-chioro-phenyl)-2,4,5,6-tetrahydro-pyrrolo[3,4- 331 clpyrazole; and 338 3-(4-Fluoro-phenyl)-2-isopropyl-5,7-dimethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene.80. The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- 59 azulene; 74 3-(4-Chloro-phenyl)-1-(3-methyl-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 75 3-(4-Chloro-phenyl)-1-(4-fluoro-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 76 3-(4-Chloro-phenyl)-1-(3-fluoro-benzyl)-1,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 103 3-(4-Chloro-phenyl)-1-thiophen-2-ylmethyl-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 104 1-Benzyl-3-thiophen-2-yl-1,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 108 3-(4-Chloro-phenyl)-1-(2,4-difluoro-benzyl)-1,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 160 4-[3-(4-Chloro-phenyl)-5,6,7,8-tetrahydro-4 H-1,2,6-triaza-azulen-1- yimethyl]-2-fluoro-phenol;1-Benzyl-3-(4-chloro-phenyl)-6-methyl-1,4,5,6,7,8-hexahydro-1,2,6- 165 triaza-azulene; 1-Benzyl-3-(4-chloro-phenyl)-6-ethyl-1,4,5,6,7,8-hexahydro-1,2,6- 166 triaza-azulene; 214 2-Ethyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 2-Ethyl-3-(4-ethyl-phenyl)-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza- 257 azulene; and 1-Benzyl-3-(4-chloro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- 273 azulene citrate salt.31. The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 1a1 3-(4-Chloro-phenyl)-2-isobutyi-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 133 2-Benzyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 177 2-Cyclohexyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 178 3-(4-Chloro-phenyl)-2-cyclohexyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azuiene; 181 3-(4-Chloro-phenyl)-2cyclopentyl-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 182 2-Cyclopentyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 183 2-(1-Ethyl-propyl)-3-(3-fiuoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 184 2-(1-Ethyl-propyl)-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 186 2-(1-Ethyl-propyl)-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 191 2-(1-Ethyl-propyl)-3-thiophen-2-yi-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 215 2-tert-Butyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene: 16 2-tert-Butyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene;217 2-Cyclopentyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza-azulene; 2-Cyclopentyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro- 218 1,2,6-triaza-azulene; 2-Cyclopentyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 220 triaza-azulene; 2-Cyclopentyl-3-(3,4-difluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- 236 triaza-azulene; 038 3-(4-Chloro-phenyl)-2-cyclobutyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 041 3-(3-Chloro-4-fluoro-phenyl)-2-cyclopentyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 042 2-sopropyl-3-(4-methoxy-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 077 2-Cyclobutyl-3-(4-fluoro-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; : 278 2-Cyclobutyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 079 2-Cyclobutyl-3-(4-triflucromethyl-phenyl)-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; : 284 2-Cyclopropyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 300 2-sec-Butyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 302 2-Cyclopentyl-3-(4-fluoro-phenyl)-6-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; 306 3-(4-Fluoro-phenyl)-2-isopropyl-8-methyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza-azulene; and 310 2-Cyclopentyl-7-methyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene.32. . The compound of claim 1 selected from the group consisting of: EX CHEMICAL NAME 47 1-Benzyi-3-(4-fluoro-phenyl)-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 64 3-(4-Chloro-phenyl)-2-ethyl-2,4,5,6,7,8-hexahydro- 1,2,6-triaza- azulene;118 3-(4-Chloro-phenyl)-1-isobutyl-1,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 180 2-Cyclopentyl-3-phenyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 190 3-(4-Fluoro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 192 2-Cyclopentyl-3-thiophen-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 209 2-1sopropyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; 210 3-(4-Ethyl-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 011 3-(4-Chloro-phenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 212 4-(2-Isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulen-3-yl)- benzonitrile; 213 2-1sopropyl-3-(4-trifluoromethyl-phenyl)-2,4,5,6,7,8-hexahydro-1,2,6- triaza-azulene; 030 2-Cyclopentyl-3-furan-3-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 233 2-Cyclopentyl-3-thiophen-2-yl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene; 284 2-Cyclopropyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1 ,2,6-triaza-azulene; 300 2-sec-Butyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; and 315 2-Isopropyl-7-methyl-3-p-tolyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza- azulene.33. The compound of claim 1 wherein said pharmaceutically acceptable salt is an effective amino addition salt.34. The compound of claim 1 wherein said pharmaceutically acceptable sait is selected from the group consisting of hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate.35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compound having serotonin receptor modulator activity of formula (1), (11), or (Ill): : R2 CYC-(ALK), CYCHALKIN NA" CYC-ALK)—N NA N y ) Ar ES BY BS ES (I (11) (II) wherein mis 0, 1or2; nis1,2o0r3; pis 1, 2 or 3, with the proviso that where m is 1, p is not 1; m+n is less than or equal to 4; : m+p is less than or equal to 4; qisOor1; ris0,1,2,3,4,0r5; R%is -Ci4alkyl, allyl, propargyi, or benzyl, each optionally substituted with -C1aalkyl, —OH, or halo; Ar is an aryl or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC4alkyleneO-, -(CHa)o.sNH-, -(CH2)1.2NH(CHy)-, -(CHy)2.3N(C1-qalkyl)- or ~(CH2)1.2N(C1.4alkyl)(CHo)-; R'is selected from the group consisting of OH, -C+ alkyl, -OC;.galkyl, -Cz.¢alkenyl, -OCs alkenyl, -Ca.galkynyl, -OCsealkynyl, -CN, -NO,, -N(R*)R? (wherein RY and RZ are independently selected from H or Cy.salkyl), -(C=O)N(R")R?, -(N-R)COR, -(N-R")SO-C.salkyl (wherein R'is H or Cy.alkyl),-(C=0)C1alkyl, -(S=(O)n)-C,.calkyl (wherein n is selected from 0, 1 or 2), -SO2N(R*)R?, -SCF3, halo, -CF3, -OCF3, -COOH and -COOC.¢alkyl; b) pheny! or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(C.4alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R"; c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R'; d) naphthyl, optionally mono-, di- or tri-substituted with R';"15 e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C4alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R'; and fy a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R';g) phenyl! or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R";ALK is a branched or unbranched C,.galkylene, Cz.salkenylene, Czsalkynylene or Cascycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC1salkyl, -OCsscycloalkyl, -CN, -NO,, -N(R®)R® (wherein R* and R® are independently selected from H, C1 .alkyl or Coealkenyl), (C=0)N(R*R®, -(N-R°)COR®, -(N-R%)SO.C1.salkyl (wherein R® is H or Ci.galkyl), -(C=0)C1.ealkyl, -(S=(0)q)-C1salkyl (wherein d is selected from 0, 1 or 2),-SO.N(R)R®, -SCF3, halo, -CF3, -OCF3, -COOH and -COOC alkyl; CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -OC,.salkyleneO-, -(CHz)2.3NH-, -(CH2)1.2NH(CH2)-, -(CHz)2-3N(C1alkyl)- or ~(CHz2)1.2N(C14alkyl)(CH)-; R% is selected from the group consisting of —OH, -C1.salkyl, -OC1.galkyl, -Cs.ecycloalkyl, -OCa.gcycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R® and R® are independently selected from H, C.alkyl or Co¢alkenyl, or R? and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C,4alkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R*R®, ~(N-R°)COR®, -(N-R°)S02C;.¢alkyl (wherein R® is H or Cyalkyl or two R® in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO2C,.salkyl)z, -(C=0)C.salkyl, -(S=(0)q4)-C1-salky! (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCFs3, halo, -CF3, -OCFa, -COOH and -COOC, galkyl; ii) phenyl! or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, NH or >N(C,4alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R%,iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY,iv) naphthyl, optionally mono-, di- or tri-substituted with RY;v) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >8, >NH or >N(C,.alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with RY;vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or , two carbon atoms replaced by —N=, optionally mono- or di-substituted with RY and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R%;vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R% and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R% and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NRY, having 0, 1 or 2 unsaturated bonds,having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having O to 5 substituents R%; R'is selected from the group consisting of H, C,.7alkyl, Co.7alkenyl, Ca.7alkynyl,Cs.zcycloalkyl, CarcycloalkylC4.7alkyl, Ca scycloalkenyl,Cs.7cycloalkenylCs.7alkyl and benzo-fusedC,.scycloalkyl, each optionally mono-, di-, or tri-substituted with RP; RP is selected from the group consisting of -OH, -OC4.alkyl, -Cs-ecycloalkyl, -OCsgcycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®)R" (wherein R® and R" are independently selected from H or Cyealkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C4alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R®)R", -(N-R")COR", -(N-R")SO.C;salkyl (wherein R" is H or C,.galkyl or two R" in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C.galkyl, -(S=(O)n)-C1-salkyl (wherein n is selected from 0, 1 or 2), -SO2N(R®*)R", -SCF3, halo, -CFa, -OCFs, -COOH and -COOC,.galkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C,ealkyl, -OC;.galkyl, -CN, -NO», -N(R*)R® (wherein R® and R® are independently selected from H, Ci-ealkyl or Ca-salkenyl), -(C=0)N(R*)R®, -(N-R°)COR®, -(N-R%)S0O,C, salkyl (wherein R® is H or C.galkyl), -(C=0)C1.salkyl, -(S=(0)q)-C.calkylPCT/US2004/030190 ® (wherein d is selected from 0, 1 or 2), -SO,N(R?*)R®, -SCF,, halo, - CF;, -OCF,, -COOH and —COOC, salkyl; R? is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C,,alkynyl and C, cycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.36. Use of a compound having serotonin receptor modulator activity of formula (I), (II), or (lll): R? CYC{ALK), CYCHALK)g—N Ar CYC-ALK)—N" "NS Ar % § ) Ar m Vr m Ls ” Lar (1) (I) (11) wherein mis 0, 1 or 2; nis 1, 2or3; pis 1, 2 or 3, with the proviso that where mis 1, pis not 1; m+n is less than or equal to 4; m+p is less than or equal to 4; qisOorf1; riso,1,2,3,4,orb5; R? is -C, alkyl, allyl, propargyl, or benzyl, each optionally substituted with-C,.;alkyl, —OH, or halo; Aris an aryl or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC, alkyleneO-, -(CH,), ;NH-, «(CH,)1.,NH(CH,)-, -(CH,),.sN(C, salkyl)- or -(CH,),..N(C,alky)(CH,)~; R'is selected from the group consisting of —-OH, -C, alkyl, -OC, salkyl, -C, alkenyl, -OC, alkenyl, -C, alkynyl, -OC,qalkynyl, -CN, -NO,, -N(R*)R? (wherein R’ and R* are independently selected from H or C, salkyl), -(C=0)N(R")R?, - 285 - AMENDED SHEETPCT/US2004/030190 ® -(N-R"YCOR, -(N-R")S0,C, salkyl (wherein R'is H or C, alkyl), -(C=0)C, alkyl, -(5=(0),)-C, ;alkyl (wherein n is selected from 0, 1 or 2), -SO,N(R")R?, -SCF;, halo, -CF,, -OCF,, -COOH and -COOC, alkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0O, >S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R";c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R';d) naphthyl, optionally mono-, di- or tri-substituted with R;e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R’; and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R;g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R"; - 286 - AMENDED SHEETPCT/US2004/030190 ® ALK'is a branched or unbranched C.salkylene, C,salkenylene, C,salkynylene or C;4cycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC, alkyl, -OC, sCycloalkyl, -CN, -NO,, -N(R*)R® (wherein R? and R® are independently selected from H, C,salkyl or C, salkenyl), (C=0)N(R3R®, -(N-R°)COR®, -(N-R°)SO,C, alkyl (wherein R° is H or C, alkyl), -(C=0)C, zalkyl, -(8=(0),)-C, salky! (wherein d is selected from 0,1o0r2), -SO,N(R?)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOQC, salkyl; CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R? or di-substituted on adjacent carbons with -OC, jalkyleneO-, -(CH,),sNH-, (CH). NH(CH,)-, -(CH,), ;N(C, alkyl)- or “(CHZ):oN(C, ,alkyl)(CH,)-; R%is selected from the group consisting of —OH, -C, salkyl, -OC, salkyl, -C; ¢Cycloalkyl, -OC; scycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C alkyl or C,salkenyl, or R? and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=0O)N(R*R?, «(N-R°)COR®, -(N-R)S0O,C, salkyl (wherein Ris H or C, alkyl or two R® in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO,C, calkyl),, ~(C=0)C, alkyl, -(8=(0),)-C, alkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF,, halo, -CF,, -OCF;, -COOH and -COOC, ;alkyl; if) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0, >S, >NH or >N(C, alkyl) and which moiety has up to one additional - 287 - AMENDED SHEET I —J —— EE.PCT/US2004/030190 ® carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with Re: iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with Re: iv) naphthyl, optionally mono-, di- or tri-substituted with R®: Vv) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0O, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by ~N=, optionally mono- or di-substituted with R? and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with Re: vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R* and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R®: vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NRSY having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R% and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NRS, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or - 288 - AMENDED SHEET J ———PCT/US2004/030190 ® an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR", having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RY;R'is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C, alkynyl, C,,cycloalkyl, C;,cycloalkylC, alkyl, C, cycloalkenyl, C,,cycloalkenylC, ;alkyl and benzo-fusedC, ;cycloalkyl, each optionally mono-, di-, or tri-substituted with R®;RP is selected from the group consisting of —OH, -OC, salkyl, -C, cycloalkyl, -OC, scycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®)R" (wherein R®* and R" are independently selected from H or C, zalkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, ,alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R®*)R®, -(N-R)CORY, -(N-R")SO,C, alkyl (wherein R" is H or C, salkyl or twoRY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, zalkyl, -(S=(0),)-C,¢alkyl (wherein n is selected from 0, 1 or 2), -SO,N(R°)R", -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, zalkyl, wherein the foregoing phenyl, pyridyl,thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, alkyl, -OC, alkyl, -CN, -NO,, -N(R*)R® (wherein R® and R® are independently selected from H, C, salkyl or C,salkenyl), (C=0)N(R*R®, -(N-R*)COR®, -(N-R°)SO,C, ;alkyl(wherein Ris H or C, salkyl), (C=0)C, salkyl, -(S=(0)4)-C, alkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF;, halo, -CF,, -OCF,, -COOH and -COOC, salkyl,R? is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C, alkynyl and C, cycloalkyl;- 289 - AMENDED SHEETPCT/US2004/030190 ® and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof; in the preparation of a medicament for the treatment or prevention of a CNS disorder selected from the group consisting of: sleep disorders, depression/anxiety, generalized anxiety disorder, schizophrenia, bipolar disorders, psychotic disorders, obsessive-compulsive disorder, mood disorders, post-traumatic stress and other stress-related disorders, migraine, pain, eating disorders, obesity, sexual dysfunction, metabolic disturbances, hormonal imbalance, alcohol abuse, addictive disorders, nausea, inflammation, centrally mediated hypertension, sleep/wake disturbances, jetlag, and circadian rhythm abnormalities in mammals, suffering therefrom.37. Use of claim 36 wherein said CNS disorder is selected from the group consisting of: depression/anxiety, sleep disorders, and circadian rhythm abnormalities.38. Use of a compound having serotonin receptor modulator activity of formula (1), (11), or (11): R? CYC-(ALK), N N CYCHALK)N SA" cyC-(ALK)—NT SA 4 ) Ar — RY), = R%), Mn BE Je " Mn Tk Tk Tk (1) (I) (III) wherein mis0,1or2; nis1,2or3; pis 1, 2 or 3, with the proviso that where mis 1, p is not 1; m+n is less than or equal to 4; m+p is less than or equal to 4; qisOorf; ris0,1,2,3,4,or5; - 290 - AMENDED SHEETPCT/US2004/030190 ® R? is -C, 4alkyl, allyl, propargyl, or benzyl, each optionally substituted with-C, ;alkyl, —OH, or halo;Aris an aryl or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC,_alkyleneO-, -(CH,), ;NH-, -(CH,), ,NH(CH,)-, (CH,),sN(C, _alkyl)- or -(CH,),,N(C,_ alkyl )}(CH,)-; R'is selected from the group consisting of —OH, -C, salkyl, -OC, qalkyl, -C, salkenyl, -OC, ;alkenyl, -C, alkynyl, -OC, alkynyl, -CN, -NO,, -N(R")R* (wherein RY and R* are independently selected from H or C, salkyl), (C=0O)N(R")R?, -(N-R")COR, -(N-R"YSO,C, salkyl (wherein R'is H or C, salkyl), -(C=0)C, 4alkyl, -(S=(0),)-C, alkyl (wherein n is selected from 0, 1 or 2), -SO,N(RY)R?, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, alkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0O, >S, >NH or >N(C, ,alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R’;c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —-N=, the fused rings optionally mono-, di- or tri-substituted with R’;d) naphthyl, optionally mono-, di- or tri-substituted with R';e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R; and-291 - AMENDED SHEETPCT/US2004/030190 ® f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R";g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di-or tri-substituted with R';ALK is a branched or unbranched C, ;alkylene, C,alkenylene, C, alkynylene or C,scycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH,-OC,4alkyl, -OC, (cycloalkyl, -CN, -NO,, -N(R*R® (wherein R* and R® are independently selected from H, C, ;alkyl or C, alkenyl), -(C=0)N(R*R®,-(N-R°)COR®, -(N-R%)SO,C, alkyl (wherein R® is H or C, zalkyl),-(C=0)C, galkyl, -(S=(0),)-C,calkyl (wherein d is selected from 0, 1 or 2),-SO,N(R*R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, salkyl;CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of:i) phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -OC, ,alkyleneO-, -(CH,), ;NH-, «(CHo)1.NH(CH,)-, (CH), ,N(C, 4alkyl)- or -(CH,); ,N(C; salky)(CHo)-; R? is selected from the group consisting of —OH, -C, salkyl,-0OC, salkyl, -C, scycloalkyl, -OC, ;cycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, salkyl or C, alkenyl, or R® and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, ,alkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R*)R®, -(N-R°)COR¢, -(N-R%)SO,C, alkyl (wherein R® is H or C, salkyl or two R° in the-292 - AMENDED SHEETPCT/US2004/030190 ® same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO,C, salkyl),, -(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein d is selected from 0, 1 or 2), -SO,N(R?)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, qalkyl,ii) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O,>S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring,which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R¢;iv) naphthyl, optionally mono-, di- or tri-substituted with RS,v) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0O, >S, >NH or >N(C, ,alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with RY and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R?,vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with RS;vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NRS, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally-293 - AMENDED SHEETPCT/US2004/030190 ® having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R? and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NRS, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RS; R' is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C, alkynyl, C, cycloalkyl, C, ;cycloalkylC, alkyl, C, cycloalkenyl, C,cycloalkenylC, ;alkyl and benzo-fusedC, ;cycloalkyl, each optionally mono-, di-, or tri-substituted with R®; RP” is selected from the group consisting of —OH, -OC, zalkyl, -C, cycloalkyl, -OC, (cycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®*)R" (wherein R® and R" are independently selected from H or C, salkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R°)R", -(N-R")CORY, -(N-R")SO,C, salkyl (wherein R" is H or C, salkyl or two RY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, salkyl, -(S=(0),)-C, alkyl (wherein n is selected from 0, 1 or 2), -SO,N(R*)R", -SCF,, halo, -CF,, -OCF;, -COOH and -COOC, zalkyl, wherein the foregoing phenyl, pyridyl, - 294 - AMENDED SHEETPCT/US2004/030130 ® thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, alkyl, -OC, salkyl, -CN, -NO,, -N(R*)R" (wherein R® and R® are independently selected from H, C, ;alkyl or C, alkenyl), (C=0)N(R*)R®, -(N-R°)COR®, -(N-R)SO,C, alkyl (wherein R® is H or C, salkyl), -(C=0)C, salkyl, -(S=(0),)-C, salky! (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, zalkyl; R? is selected from the group consisting of H, C, alkyl, C, alkenyl, C, alkynyl and C, cycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof; in the preparation of a medicament for the treatment or prevention of a disease or condition selected from the group consisting of. hypotension, peripheral vascular disorders, cardiovascular shock, renal disorders, gastric motility, diarrhea, spastic colon, irritable bowel disorders, ischemias, septic shock, urinary incontinence, and other disorders related to the gastrointestinal and vascular systems in mammals, suffering therefrom.39. Use of a compound having serotonin receptor modulator activity of formula (I), (II), or (I): R? CYCAALK)q CYCHALK)—N" SA" oye (ALK) —N NA % N ) Ar ) kr : Rr i Rk! (1) (11) (I) wherein mis 0, 1 or 2; nis 1, 2or3; pis 1, 2or3, with the proviso that where mis 1, pis not 1; m+n is less than or equal to 4; m+p is less than or equal to 4; - 295 - AMENDED SHEETPCT/US2004/030190 ® qgisOor1, ris0,1,2, 3,4, or5; R? is -C, alkyl, allyl, propargyl, or benzyl, each optionally substituted with -C, alkyl, —OH, or halo; Aris an aryl or heteroaryl ring selected from the group consisting of:a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC, _alkyleneO-, -(CH,), ;NH-, -(CH,),.,NH(CH,)-, -(CH,),3N(C, alkyl)- or -(CH,),,N(C, ,alkyl)(CH,)-; R'is selected from the group consisting of -OH, -C, salkyl,-0OC, zalkyl, -C, alkenyl, -OC, calkenyl, -C, salkynyl, -OC, alkynyl, -CN, -NO,, -N(R")R? (wherein RY and R* are independently selected from H or C, alkyl), -(C=O)N(R")R?, -(N-R)COR, -(N-R")SO,C, salkyl (wherein R'is H or C, alkyl), -(C=0)C, alkyl, -(S=(0),)-C, alkyl (wherein n is selected from 0, 1 or 2), -SO,N(R")R?, -SCF,, halo, -CF;, -OCF;, -COOH and -COO0C, qalkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O,>S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R";c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring,which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R";d) naphthyl, optionally mono-, di- or tri-substituted with R',e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or- 296 - AMENDED SHEETET.PCT/US2004/030190 ® pyridofused moiety is optionally mono-, di-, or tri-substituted with R": and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by ~N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R'; g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R": ALK is a branched or unbranched C.salkylene, C,salkenylene, C,salkynylene or C; gcycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC, salkyl, -OC, <Cycloalkyl, -CN, -NO,, -N(R*)R’ (wherein R? and R® are independently selected from H, C,salkyl or C,salkenyl), ~(C=O)N(R*R®, -(N-R°)COR, «(N-R)SO,C, alkyl (wherein R® is H or C, alkyl), -(C=0)C, salkyl, «(S=(0)y)-C, alkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF,, halo, -CF;, -OCF,, -COOH and -COOC, alkyl: CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -OC,alkyleneO-, -(CH,),.sNH-, -(CH,), ,NH(CH,)-, «(CH,),sN(C,_alkyl)- or -(CH,),.N(C, <alkyl)(CH,)-; R%is selected from the group consisting of OH, -C, calkyl, -OC, alkyl, -C; cycloalkyl, -OC, cycloalkyl, phenyl, -Ophenyi, benzyl, -Obenzyl, -CN, -NO,, -N(R*R® (wherein R® and R® are independently selected from H, C, alkyl or C.salkenyl, or R® and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl), optionally having one carbon substituted with -OH, and optionally having one or two - 297 - AMENDED SHEET J ———PCT/US2004/030190® unsaturated bonds in the ring), -(C=0O)N(R?*R®, -(N-R°)COR¢, -(N-R%)SO,C, salkyl (wherein R® is H or C, alkyl or two R® in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring,said ring having 4 to 6 members), -N-(SO,C, qalkyl),, -(C=0)C, alkyl, -(S=(0),)-C,alky! (wherein d is selected from O, 1 or 2), -SO,N(R®*)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, alkyl; ii) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;iv) naphthyl, optionally mono-, di- or tri-substituted with R¥,v) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0O, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R* and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R?,vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with RS;vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected - 298 - AMENDED SHEETPCT/US2004/030190 ® from O, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R? and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R% and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RY; R' is selected from the group consisting of H, C, alkyl, C, alkenyl, C, alkynyl, C, cycloalkyl, C,,cycloalkylC, alkyl, C, cycloalkenyl, C,,cycloalkenylC, ,alkyl and benzo-fusedC, ;cycloalkyl, each optionally mono-, di-, or tri-substituted with RP; RP is selected from the group consisting of -OH, -OC, salkyl, -C, (cycloalkyl, -OC, ccycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®)R" (wherein R® and R* are independently selected from H or C, ;alkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0O)N(R®*)R", -(N-R")CORY, -(N-R")SO,C, salkyl (wherein R" is H or C, salkyl or two Rin the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, salkyl, -(S=(0),)-C, alkyl! (wherein - 299 - AMENDED SHEETPCT/US2004/030190 ® n is selected from 0, 1 or 2), -SO,N(R®)R", -SCF,, halo, -CF;, -OCF,, -COOH and -COOC, qalkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, alkyl, -OC, salkyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, alkyl or C,salkenyl), -(C=0)N(R®)R®, -(N-R°)COR®, -(N-R°)SO,C, salkyl (wherein R® is H or C, alkyl), -(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, 4alkyl, R? is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C,,alkyny! and C, cycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof; in the preparation of a medicament for the treatment or prevention of an ocular disorder selected from the group consisting of. glaucoma, optic neuritis, diabetic retinopathy, retinal edema, and age-related macular degeneration in mammals suffering therefrom.40. Use of a compound having serotonin receptor modulator activity of formula (1), (II), or (il): R? CYCAALK)q CYCAALK)—N" NA" oye (ALK)—N" NAT oe N ) Ar Tk Tw Tk (1) (11) (11) wherein mis 0, 1 or 2; nis 1,2 or3; pis 1, 2or3, with the proviso that where mis 1, p is not 1; m+n is less than or equal to 4; m+p is less than or equal to 4; - 300 - AMENDED SHEETPCT/US2004/030190 ® qisOori; ris0,1,2,3,4,0r5; R3 is -C, alkyl, allyl, propargyl, or benzyl, each optionally substituted with -C, alkyl, —OH, or halo; Aris an aryl or heteroaryl ring selected from the group consisting of:a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC, jalkyleneO-, -(CH,), ;NH-, (CH,),.,NH(CH,)-, (CH,),.;N(C_alkyl)- or (CH), .N(C, salkyl)(CH,)-; R" is selected from the group consisting of —OH, -C, alkyl,-0OC, ¢alkyl, -C, alkenyl, -OC, salkenyl, -C,salkynyl, -0C,¢alkynyl, -CN, -NO,, -N(R")R? (wherein R* and R* are independently selected from H or C, alkyl), -(C=O)N(R")R?, -(N-R)COR!, (N-R)SO,C, salkyl (wherein R'is H or C,zalkyl), -(C=0)C, salkyl, -(S=(0),)-C, alkyl (wherein n is selected from 0,1 or 2), -SO,N(R")R?, -SCF,, halo, -CF,, -OCF;, -COOH and -COOC, zalkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O,>S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R";c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring,which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R';d) naphthyl, optionally mono-, di- or tri-substituted with R';e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0O, >S, >NH or >N(C, ,alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or - 301 - AMENDED SHEETPCT/US2004/030190 ® pyridofused moiety is optionally mono-, di-, or tri-substituted with R": and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R"; g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R": ALK is a branched or unbranched C,salkylene, C,salkenylene, C, salkynylene or C; gcycloalkenylene, optionally mono-, di-, or tri-substituted with a 16 substituent independently selected from the group consisting of: -OH, -OC, zalkyl, -OC;¢cycloalkyl, -CN, -NO,, -N(R*)R® (wherein R®* and R® are independently selected from H, C, alkyl or C, salkenyl), -(C=0O)N(R*R, -(N-R*)COR®, «(N-R)SO,C, alkyl (wherein R® is H or C, alkyl), ~(C=0)C, salkyl, «(8=(0),)-C, salky! (wherein d is selected from 0, 10r2), -SO,N(R?)R®, -SCF,, halo, -CF;, -OCF;, -COOH and -COOC, qalkyl; CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R? or di-substituted on adjacent carbons with -OC, alkyleneO-, -(CH,), ;NH-, ~(CH,); ,NH(CH,)-, -(CH,),,N(C,_jalkyl)- or -(CH,),.,N(C, salkyl)(CH,)-; Ris selected from the group consisting of —OH, -C, alkyl, -OC, alkyl, -C, sCycloalkyl, -OC,; ¢cycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R"® (wherein R? and R® are independently selected from H, C, alkyl or C,salkenyl, or R® and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl), optionally having one carbon substituted with -OH, and optionally having one or two - 302 - AMENDED SHEET I —PCT/US2004/030190 ® unsaturated bonds in the ring), -(C=0)N(R*)R?, -(N-R°)COR®, -(N-R)SO,C, salkyl (wherein R® is H or C, alkyl or two Re in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO,C, alkyl), -(C=0)C, alkyl, «(8=(0),)-C, alkyl (wherein d is selected from 0, 1 0r2), -SO,N(R*)R?, -SCF;, halo, -CF,, -OCF;, -COOH and -COOC, 4alkyl: if) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0, >S, >NH or >N(C, 4alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —-N=, the fused rings optionally mono-, di- or tri-substituted with RS;iv) naphthyt, optionally mono-, di- or tri-substituted with R*:Vv) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C_alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R9:vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R? and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R*: vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ning having 0, 1 or 2 non-adjacent heteroatom members selected - 303 - AMENDED SHEET I ———PCT/US2004/030190 ® from O, S, -N=, >NH or >NRS®, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents RY and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?Y, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR?9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents R®; R'is selected from the group consisting of H, C, alkyl, C, alkenyl, C, alkynyl, C,cycloalkyl, C,,cycloalkylC, ;alkyl, C, cycloalkenyl, C,cycloalkenylC, ;alkyl and benzo-fusedC, cycloalkyl, each optionally mono-, di-, or tri-substituted with RP; RP is selected from the group consisting of —OH, -OC, salkyl, -C, scycloalkyl, -OC, cycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®*)R" (wherein R®* and R" are independently selected from H or C, salkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, jalkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R®)R", -(N-R")CORY, -(N-R%)S0O,C, salkyl (wherein R" is H or C, alkyl or two R" in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, salkyl, -(S=(0),)-C, salkyl (wherein - 304 - AMENDED SHEETEEE. PCT/US2004/030190 ® nis selected from 0, 1 or 2), -SO,N(R*)R?, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, salkyl, wherein the foregoing phenyl, pyridyl, thienyl, furany! and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, salkyl, -OC, alkyl -CN, -NO,, -N(R?)R® (wherein R® and R? are independently selected from H, C, alkyl or C,salkenyl), -(C=O)N(R*)R?, -(N-R°)COR®, -(N-R°)SO,C, salky! (wherein R° is H or C, alkyl), -(C=0)C, alkyl, +(8=(0),)-C, calkyl (wherein d is selected from 0.10r2), -SO,N(R*R®, -SCF;, halo, -CF,, -OCF,, -COOH and -COOC, zalkyl; R? is selected from the group consisting of H, C, ,alkyl, C.,..alkenyl, C,.;alkynyl and C, ;cycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof: in the preparation of a medicament for the treatment or prevention of a disease or condition selected from the group consisting of: depression/anxiety, sleep/wake disturbances, jetlag, migraine, urinary incontinence, gastric motility, and irritable bowel disorders in mammals, suffering therefrom.41. Useofa compound having serotonin receptor modulator activity of formula (I), (II), or (IH): R? CYCLALK), CYCHALK)—N" Ny —Ar CYCHALK)—N" Ar '¢ ) Ar ER RR EER (1) (11) (III) wherein mis 0, 1 or 2; nis 1, 2or3; : pis 1, 2or3, with the proviso that where mis 1, pis not 1: m+n is less than or equal to 4; m+p is less than or equal to 4; - 305 - AMENDED SHEET I —EE EE, PCT/US2004/030190 ® qisOor1: ris0, 1,2, 3, 4, or 5; R®is -C, alkyl, allyl, propargyl, or benzyl, each optionally substituted with-C,.salkyl, —OH, or halo: Arisanarylor heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -0C, ,alkyleneO-, -(CH,), ;NH-, “(CH,);..NH(CH,)-, -(CH,).sN(C, ,alkyl)- or (CH): .N(C,Lalkyl)(CH,)-; R'is selected from the group consisting of —~OH, -C, alkyl, -OC, alkyl, -C, salkenyl, -OC, salkenyl, -C, alkynyl, -OC, alkynyl, -CN, -NO,, -N(R")R? (wherein RY and R? are independently selected from H or C, alkyl), ~(C=O)N(R")R?, -(N-R')COR, -(N-R')SO,C, salkyl (wherein R'is H or Ci zsalkyl), <(C=0)C, alkyl, «(8=(0),)-C, alkyl (wherein n is selected from 0, 1 or 2), -SO,N(RYR?, -SCF;, halo, -CF,, -OCF;, -COOH and -COOC, 4alkyl; b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >Q, >S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R’; c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R"; d) naphthyl, optionally mono-, di- or tri-substituted with R" e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or - 306 - AMENDED SHEET I — --EE —— PCT/US2004/030190 ® pyridofused moiety is optionally mono-, di-, or tri-substituted with R": and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R" g) phenyl! or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R"; ALK is a branched or unbranched Cisalkylene, C, salkenylene, C, alkynylene or C,4cycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC, zalkyl, -OC, 4cycloalkyl, -CN, -NO,, -N(R*)R® (wherein R? and R? are independently selected from H, C, alkyl or C, salkenyl), -(C=0)N(RR?, -(N-R°)CORS, -(N-R°)SO,C, salkyl (wherein R® is H or C, alkyl), -(C=0)C,zalkyl, «(S=(0),)-C, salky! (wherein d is selected from 0, 1 or 2), -SO,N(R®)R?, -SCF,, halo, -CF;, -OCF,, -COOH and -COOC, alkyl; CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of: i) phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -0OC, ,alkyleneO-, -(CH,), ,NH-, «(CH,), .NH(CH,)-, -(CH,),3N(C, 4alkyl)- or -(CH,),.N(C, <alkyl)(CH,)-; R%is selected from the group consisting of ~OH, -C alkyl, -OC,zalkyl, -C, sCycloalkyl, -OC, sCycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R? and R® are independently selected from H, C,salkyl or C, salkenyl, or R? and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, alkyl), optionally having one carbon substituted with -OH, and optionally having one or two - 307 - AMENDED SHEET IE ———EE aE EEE, PCT/US2004/030190 ® unsaturated bonds in the ring), «(C=O)N(R*)R®, -(N-R)COR, «(N-R%)SO,C, salkyi (wherein R¢ is H or C,salkyl or two RC in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO,C, salkyl),, -(C=0)C, alkyl, -(8=(0)y)-C, salkyl (wherein d is selected from 0, 1 0r2), -SO,N(R*R", -SCF;, halo, -CF,, -OCF;, -COOH and -COOC, alkyl; if) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >0,>S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionaily replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RS;ii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by -N= the fused rings optionally mono-, di- or tri-substituted with R®;iv) naphthyl, optionally mono-, di- or tri-substituted with RS;Vv) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R?;vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by ~N=, optionally mono- or di-substituted with R? and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R: vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected - 308 - AMENDED SHEET I ——————PCT/US2004/030190 ® from O, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R? and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR?", having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl! and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NR?, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RS, R'is selected from the group consisting of H, C, ;alkyl, C, alkenyl, C, alkynyl, C, cycloalkyl, C, ;cycloalkylC, ;alkyl, C, cycloalkenyl,C,.,cycloalkenylC, ;alkyl and benzo-fusedC, cycloalkyl, each optionally mono-, di-, or tri-substituted with R®; RP” is selected from the group consisting of —OH, -OC, alkyl, -C, cycloalkyl, -OC, ;cycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®*)R" (wherein R®* and R" are independently selected from H or C, zalkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=0O)N(R®*)R", -(N-R")CORY, -(N-R")SO,C, alkyl (wherein R" is H or C, salkyl or two RY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein - 309 - AMENDED SHEETEe —— PCT/US2004/030190 nis selected from 0, 1 or 2), -SO,N(R)RY, -SCF;, halo, -CF,, -OCF,, -COOH and -COOC, (alkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, salkyl, -OC, ,alkyl, -CN. -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, alkyl orC.salkenyl), -(C=O)N(R?)R?, -(N-R°)COR, «(N-R")SO,C, alkyl (wherein R° is H or C,salkyl), -(C=0)C,salkyl, «(§=(0),)-C, salky! (wherein d is selected from 0, 1 or 2), -SO,N(R*R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, alkyl; R? is selected from the group consisting of H, C, alkyl, C..,alkenyl, C, alkynyl and C, ,cycloalkyl; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof; in the preparation of a medicament for the treatment or prevention of a disease or condition selected from the group consisting of: depression/anxiety, generalized anxiety disorder, schizophrenia, bipolar disorders, psychotic disorders, obsessive-compulsive disorder, mood disorders, post-traumatic stress disorders, sleep disturbances, sexual dysfunction, eating disorders, migraine, addictive disorders, and peripheral vascular disorders in mammals suffering therefrom.42. A method of making a compound of formula (XVI) comprising the step of reacting a compound of formula (XXXV) with a compound of formula (XIV): Hn NOTE CYC-ALK)—N otf 5 = CYC-(ALK)4-X 5 )= (R ol, (XIV) (R = ON oT - G G 05 OX) (XVI) wherein Gis -C, alkyl, -COOC, ;alkyl, -(C=0)C, alkyl, or benzy! unsubstituted or substituted with -OC, ;alky! or -C,salkyl; Xis Cl, Br, I, OMs, or OTs: mis0, 1or2; -310 - AMENDED SHEET J —— -PCT/US2004/030190 ® pis 1, 2 or 3, with the proviso that where mis 1, p is not 1; m+p is less than or equal to 4; qisOor1; ris0,1,2,3,4,or5; R’is-C,alkyl, allyl, propargyl, or benzyl, each optionally substituted with-C, ;alkyl, —OH, or halo;ALK is a branched or unbranched C, ;alkylene, C, alkenylene, C,zalkynyiene or C,4cycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH,-OC, salkyl, -OC, scycloalkyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, salkyl or C, alkenyl), -(C=0)N(R®)R®, -(N-R°)COR, -(N-R°)SO,C, salkyl (wherein R° is H or C, galkyl),-(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein d is selected from 0, 1 or 2),-SO,N(R*)R®, -SCF,, halo, -CF;, -OCF,, -COOH and -COOC, zalkyl;16 CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of:i} phenyl, optionally mono-, di- or tri-substituted with R® or di-substituted on adjacent carbons with -OC, ,alkyleneO-, -(CH,),,;NH-, -(CH,),,NH(CH,)-, (CH,),.;N(C,_alkyl)- or -(CH,),,N(C, _4alkyl)(CH,)-;R" is selected from the group consisting of —OH, -C, salkyl,-OC, zalkyl, -C, scycloalkyl, -OC, cycloalkyl, phenyl, -Ophenyl, benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R* and R°® are independently selected from H, C, calkyl or C, alkenyl, or R® and R° may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), (C=0)N(R*)R®, -(N-R°)COR®,-(N-R%)SO,C, salkyl (wherein Ris H or C, calkyl or two R°® in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -N-(SO,C, salkyl),, -(C=0)C, salkyl, -(S=(0),)-C,salkyl (wherein d is selected from 0, -311 - CLEAN COPYEEE PCT/US2004/030190 ® 1 or2), -SO,N(R*)R®, -SCF,, halo, -CF;, -OCF,, -COOH and -COOC, zalkyt:ii) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O,>S, >NH or >N(C, alkyl) and which moiety has up to one additional carbon atom optionally replaced by —-N=, the fused rings optionally mono-, di- or tri-substituted with RY;iii) phenyl fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R%;iv) naphthyl, optionally mono-, di- or tri-substituted with RY Vv) a monocyclic aromatic hydrocarbon group having five ring atoms,having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R? and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with RS; vi) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with Re:vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NRS, having 0, 1 or 2 unsaturated bonds,having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having Oto 5 substituents R? and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents RS and-312 - CLEAN COPY J —,————— -PCT/US2004/030190 ® viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR", having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from 0, S, -N=, >NH or >NRSY, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents RY, and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.43. The method of claim 42 wherein said compound of formula (XXXV) is H HN =O wd, (=N G prepared by treating a compound of formula (XII), (Xi) with a triflating agent.44. The method of claim 42 wherein said compound of formula (XVI) is subsequently reacted in at least one step to produce a compound of formula (i): CYCHALK)—N Ar nt CN R (In wherein Aris an aryl or heteroaryl ring selected from the group consisting of: -313 - CLEAN COPYPCT/US2004/030190 ® a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC, jalkyleneO-, -(CH,), ;NH-, -(CH,),,NH(CH,)-, -(CH,),sN(C,_,alkyl)- or -(CH,),.,N(C,_salkyl)}(CH,)-; R" is selected from the group consisting of —OH, -C, alkyl, -OC, zalkyl, -C, alkenyl, -OC, salkenyl, -C,salkynyl, -OC, alkynyl, -CN, -NO,, -N(R")R* (wherein R¥ and R* are independently selected from H or C, alkyl), -(C=0)N(R")R?, -(N-R)COR!, -(N-R")SO,C, alkyl (wherein R'is H or C, salkyl), -(C=0)C, alkyl, -(S=(0),)-C, galkyl (wherein n is selected from O, 1 or 2), -SO,N(R")R?, -SCF;, halo, -CF,, -OCF,, -COOH and -COO0C, alkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O,>S, >NH or >N(C,_ alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R';c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring,which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R';d) naphthyl, optionally mono-, di- or tri-substituted with R’;e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, ,alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R";and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent- 314 - CLEAN COPYPCT/US2004/030190 @® carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R’; g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R'; and R' is selected from the group consisting of H, C, ;alkyl, C,,alkenyl, C, alkynyl, C, ;cycloalkyl, C,,cycloalkylC, ;alkyl, C, cycloalkenyl, C, ,cycloalkenylC, alkyl and benzo-fusedC, ;cycloalkyl, each optionally mono-, di-, or tri-substituted with R?; RP is selected from the group consisting of —OH, -OC, alkyl, -C, ,cycloalkyl, -OC, scycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®)R* (wherein R®* and R" are independently selected from H or C, salkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >0, =N-, >NH or >N(C, alkyl) and optionally having one or two unsaturated bonds in the ring), (C=0)N(R®)R", -(N-RY)CORY, -(N-R")SO,C, alkyl (wherein R" is H or C, salkyl or two RY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein n is selected from 0, 1 or 2), -SO,N(R®)R", -SCF,, halo, -CF,, -OCF,, . -COOH and -COOC, zalkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, salkyl, -OC, alkyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, salkyl or C,¢alkenyl), (C=0)N(R*R®, -(N-R°)COR®, -(N-R°)SO,C, zalkyl (wherein R°® is H or C, zalkyl), -(C=0)C, alkyl, -(S=(0),)-C, alkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, ¢alkyl; - 315 - CLEAN COPYPCT/US2004/030190 ® 45. A method of making a compound of formula (XXXV) comprising the step of reacting a compound of formula (Xl) with a triflating agent: . oN 0 in Ns OTE Ne a (Xi) (XXXV) wherein Gis -C,zalkyl, -COOC, zalkyl, -(C=0)C, salkyl, or benzyl unsubstituted or substituted with -OC, salkyl or -C, salkyl; mis 0, 1 or 2; pis 1, 2 or 3, with the proviso that where mis 1, pis not 1; m+p is less than or equal to 4; ris0,1,2,3,4,0r5; R® is -C,_4alkyl, allyl, propargyl, or benzyl, each optionally substituted with -C, alkyl, —OH, or halo; and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.46. The method of claim 45 wherein said compound of formula (XXXV) is subsequently reacted in at least one step to produce a compound of formula (in: CYC-ALK);—N ay Ar (RYH~L (1 wherein qgisQorf; Ar is an ary! or heteroaryl ring selected from the group consisting of: a) phenyl, optionally mono-, di- or tri-substituted with R" or di-substituted on adjacent carbons with -OC,_jalkyleneO-, -(CH,),;NH-, -(CH,), ,NH(CH,)-, -(CH,),,N(C, ,alkyl)- or -(CH,), ,N(C,_alky!)(CH,)-; - 316 - CLEAN COPYPCT/US2004/030190 ® R" is selected from the group consisting of —OH, -C, salkyl, -0C, salkyl, -C, alkenyl, -OC, zalkenyl, -C, alkynyl, -0OC; alkynyl, -CN, -NO,, -N(R")R? (wherein R* and R* are independently selected from H or C, salkyl), -(C=0O)N(RY)R?, -(N-R)COR, -(N-R"'SO,C, salkyl (wherein R'is H or C, salkyl),-(C=0)C, galkyl, -(S=(0),)-C,qalky! (wherein n is selected from 0, 1 or 2), -SO,N(R")R?, -SCF,, halo, -CF,, -OCF;, -COOH and -COOC, alkyl;b) phenyl or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(C, ,alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R";c) phenyl fused at two adjacent ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with R';d) naphthyl, optionally mono-, di- or tri-substituted with R";e) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C, alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with R'; and f) a monocyclic aromatic hydrocarbon group having six ring atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R" and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R';-317 - CLEAN COPYPCT/US2004/030190 ® g) phenyl or pyridyl, substituted with a substituent selected from the group consisting of phenyl, pyridyl, thiophenyl, oxazolyl and tetrazolyl, where the resultant substituted moiety is optionally further mono-, di- or tri-substituted with R";ALK s a branched or unbranched C, alkylene, C, alkenylene, C, jalkynylene or C, qcycloalkenylene, optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -OC, salkyl, -OC, (cycloalkyl, -CN, -NO,, -N(R*)R® (wherein R?* and R® are independently selected from H, C, salkyl or C, salkenyl), -(C=0)N(R?*)R",-(N-R®)CORS, -(N-R®)SO,C, calkyl (wherein Ris H or C, alkyl),-(C=0)C, alkyl, -(S=(0)4)-C, alkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, salky!;CYC is hydrogen or a carbocyclic, heterocyclic, aryl or heteroaryl ring selected from the group consisting of:i) phenyl, optionally mono-, di- or tri-substituted with R? or di-substituted on adjacent carbons with -OC,_alkyleneO-, -(CH,), ;NH-, ~(CH,);,NH(CH,)-, (CH,),.sN(C,_alkyl)- or -(CH,), ,N(C, salkyl(CH,)-; Reis selected from the group consisting of —OH, -C, salkyl,-OC, salkyl, -C, scycloalkyl, -OC, cycloalkyl, phenyl, -Ophenyl,benzyl, -Obenzyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, zalkyl or C, alkenyl, or R® and R® may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O,=N-, >NH or >N(C, ,alkyl), optionally having one carbon substituted with -OH, and optionally having one or two unsaturated bonds in the ring), -(C=0)N(R*R®, -(N-R°)COR?®, -(N-R%)SO,C, alkyl (wherein R° is H or C,zalkyl or two R° in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring,said ring having 4 to 6 members), -N-(SO,C, salkyl),, -(C=0)C, alkyl, -(S=(0),)-C, salkyl (wherein d is selected from 0, 1 or 2), -SO,N(R*R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, 4alkyl; -318 - CLEAN COPYPCT/US2004/030190 @® ii) phenyl! or pyridyl fused at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O, >S, >NH or >N(C, ,alkyl) and which moiety has up to one additional carbon atom optionally replaced by —N=, the fused rings optionally mono-, di- or tri-substituted with RY;iii) phenyl! fused at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has one or two carbon atoms replaced by —-N=, the fused rings optionally mono-, di- or tri-substituted with R¥,iv) naphthyl, optionally mono-, di- or tri-substituted with R¢;v) a monocyclic aromatic hydrocarbon group having five ring atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >0, >S, >NH or >N(C,_alkyl), having up to one additional carbon atoms optionally replaced by —N=, optionally mono- or di-substituted with R* and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono-, di-, or tri-substituted with RY,vi) a monocyclic aromatic hydrocarbon group having six ring atoms,having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by —N=, optionally mono- or di-substituted with R® and optionally benzofused or pyridofused at two adjacent carbon atoms, where the benzofused or pyridofused moiety is optionally mono- or di-substituted with R%;vii) a 3-8 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected from O, S, -N=, >NH or >NR9, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, optionally having one carbon member which forms a bridge, having 0 to 5 substituents R® and optionally benzofused or pyridofused at two adjacent carbon atoms where the benzofused or pyridofused moiety has 0, 1, 2 or 3 substituents R?, and viii) a 4-7 membered non-aromatic carbocyclic or heterocyclic ring said ring having 0, 1 or 2 non-adjacent heteroatom members selected-319 - CLEAN COPYPCT/US2004/030190 ® from O, S, -N=, >NH or >NRSY, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and optionally having one carbon member which forms a bridge, the heterocyclic ring fused at two adjacent carbon atoms forming a saturated bond or an adjacent carbon and nitrogen atom forming a saturated bond to a 4-7 membered carbocyclic or heterocyclic ring, having 0 or 1 possibly additional heteroatom member, not at the ring junction, selected from O, S, -N=, >NH or >NR?Y, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and the fused rings having 0 to 5 substituents R% and R'is selected from the group consisting of H, C, alkyl, C, ,alkenyl, C, alkynyl, C, ,cycloalkyl, C, ;cycloalkylC, ;alkyl, C, cycloalkenyl, C,,cycloalkenylC, ;alkyl and benzo-fusedC, ,cycloalkyl, each optionally mono-, di-, or tri-substituted with RP; RP is selected from the group consisting of —OH, -OC, galkyl, -C, cycloalkyl, -OC, 4cycloalkyl, -CN, -NO,, phenyl, pyridyl, thienyl, furanyl, pyrrolyl, -N(R®*)R" (wherein R®* and R" are independently selected from H or C, zalkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C, alkyl) and optionally having one or two unsaturated bonds in the ring), (C=0)N(R®)R", -(N-R")CORY, ~(N-R")SO,C, alkyl (wherein R" is H or C, alkyl or two RY in the same substituent may be taken together with the amide of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 4 to 6 members), -(C=0)C, salkyl, -(S=(0),)-C, salky! (wherein n is selected from 0, 1 or 2), -SO,N(R®)R", -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, salkyl, wherein the foregoing phenyl, pyridyl, thienyl, furanyl and pyrrolyl substituents are optionally mono-, di-, or tri-substituted with a substituent independently selected from the group consisting of: -OH, -C, ;alkyl, -OC, alkyl, -CN, -NO,, -N(R*)R® (wherein R* and R® are independently selected from H, C, zalky! or C,salkenyl), -(C=0)N(R?)R®, (N-R°)COR¢, -(N-R°)SO,C, calkyl (wherein R® is H or C, salkyl), -(C=0)C, salkyl, -(S=(0),)-C, salkyl - 320 - CLEAN COPYPCT/US2004/030190 ® | (wherein d is selected from 0, 1 or 2), -SO,N(R*)R®, -SCF,, halo, -CF,, -OCF,, -COOH and -COOC, alkyl;47. A compound of claim 1 isotopically-labelled to be detectable by PET or SPECT.48. A method for studying serotonin-mediated disorders comprising the step of using an '®F-labeled or "C-labelled compound of claim 1 as a positron emission tomography (PET) molecular probe.49. A compound as claimed in claim 1 or claim 47, substantially as herein described with reference to and as illustrated in any of the examples.50. A pharmaceutical composition as claimed in claim 35, substantially as herein described with reference to and as illustrated in any of the examples.51. Use as claimed in any one of claims 36, or 38 to 41, substantially as herein described with reference to and as illustrated in any of the examples.52. A method as claimed in claim 42, substantially as herein described with reference to and as illustrated in any of the examples.53. A method as claimed in claim 48, substantially as herein described with reference to and as illustrated in any of the examples. -321- AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50452803P | 2003-09-17 | 2003-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200603031B true ZA200603031B (en) | 2007-07-25 |
Family
ID=37520186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200603031A ZA200603031B (en) | 2003-09-17 | 2006-04-13 | Fused heterocyclic componds as serotonin receptor modulators |
Country Status (4)
Country | Link |
---|---|
CN (3) | CN101318961B (en) |
CA (1) | CA2782783C (en) |
UA (1) | UA85563C2 (en) |
ZA (1) | ZA200603031B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201120586D0 (en) * | 2011-11-30 | 2012-01-11 | Ge Healthcare Ltd | Solid phase extraction neutralisation |
JPWO2017188288A1 (en) * | 2016-04-26 | 2019-02-28 | 塩野義製薬株式会社 | 5-substituted azabenzimidazole derivatives having AMPK activation action |
CN108285460A (en) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | A kind of pharmaceutical salts of EGFR kinase inhibitor and preparation method thereof and purposes |
BR112020012374A2 (en) * | 2017-12-22 | 2020-11-24 | Chemocentryx, Inc. | diaryl-substituted 5.5-fused ring compounds as c5ar inhibitors |
CN110117284B (en) * | 2018-02-06 | 2021-11-19 | 江苏奥赛康药业有限公司 | Nitrogen-containing heterocyclic compound and preparation method and application thereof |
CN110194773B (en) * | 2019-07-26 | 2019-11-22 | 上海美迪西生物医药股份有限公司 | Pyrrolo-pyrazole analog derivative, preparation method and its application in medicine |
CN112300169B (en) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | Pyrrolopyrazole derivative, preparation method and medical application thereof |
CN112300167B (en) * | 2019-07-26 | 2022-01-21 | 上海美迪西生物医药股份有限公司 | Pyrrolopyrazole derivative, preparation method and medical application thereof |
CN112390801A (en) * | 2019-08-15 | 2021-02-23 | 上海美迪西生物医药股份有限公司 | Pyrrolopyrazole derivative, preparation method and medical application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663178A (en) * | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
TW470745B (en) * | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
-
2004
- 2004-09-15 CN CN2008101315319A patent/CN101318961B/en not_active Expired - Fee Related
- 2004-09-15 CN CNA2008101315323A patent/CN101318962A/en active Pending
- 2004-09-15 CA CA2782783A patent/CA2782783C/en not_active Expired - Fee Related
- 2004-09-15 CN CN200480033737.8A patent/CN1882590B/en not_active Expired - Fee Related
- 2004-09-15 UA UAA200603249A patent/UA85563C2/en unknown
-
2006
- 2006-04-13 ZA ZA200603031A patent/ZA200603031B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101318962A (en) | 2008-12-10 |
CN1882590A (en) | 2006-12-20 |
CA2782783C (en) | 2018-03-27 |
CA2782783A1 (en) | 2005-05-06 |
UA85563C2 (en) | 2009-02-10 |
CN1882590B (en) | 2014-03-05 |
CN101318961A (en) | 2008-12-10 |
CN101318961B (en) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2539426A1 (en) | Fused heterocyclic compounds | |
ZA200603031B (en) | Fused heterocyclic componds as serotonin receptor modulators | |
RU2431635C2 (en) | Compounds and compositions as cannabinoid receptor 1 inhibitors | |
NZ565334A (en) | Pyrimidine compounds as serotonin receptor modulators | |
JP2009503076A5 (en) | ||
US6180630B1 (en) | Tricyclic pyrazolo-pyridazinone analogues as GAGA-A receptor ligands | |
WO2005077363A1 (en) | Heterocyclic gaba-a subtype selective receptor modulators | |
EP1905774B1 (en) | Fused heterocyclic compounds as serotonin receptor modulators | |
WO2007131153A2 (en) | Methods for the preparation of pyrazole-containing compounds | |
AU2011253635B2 (en) | Fused heterocyclic compounds | |
KR101168611B1 (en) | Fused heterocyclic compounds as serotonin receptor modulators | |
NZ578849A (en) | Fused heterocyclic compounds as serotonin receptor modulators | |
ZA200307023B (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors. |